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SUMMARY 
 
The Monte Carlo method can be used to simulate deterministic processes such as 
the interaction of nuclear particles with matter, using a probabilistic approach. For 
radiation transport, the method is realised using Monte Carlo radiation transport 
codes. Performing simulations often has a distinct advantage over experimental 
studies, especially when physical measurements would be impracticable or even 
impossible to undertake. The application of Monte Carlo methods to nuclear 
medicine problems can therefore be seen as advantageous.  
 
123I is a commonly utilised radionuclide for nuclear medicine diagnostic imaging and 
non-imaging investigations. The radioactive decay scheme of 123I presents particular 
challenges in terms of accurately determining the activity of an 123I based 
radiopharmaceutical prior to administration. 
 
The aims of this project were to use Monte Carlo modelling techniques to investigate 
the uncertainties associated with 123I assay and thyroid uptake assessment using 
this radionuclide. A model of the UK secondary standard calibrator was created 
using MCNP5 code and validated against the physical calibrator. A sensitivity curve 
for the instrument was created through simulation and the effect of measuring 123I 
using a vial and a syringe investigated. Up to 21% variation was seen between the 
vial and the syringe geometries studied.    
 
A thyroid uptake counter model was produced to determine uncertainties in thyroid 
uptake assessment for a number of different parameters. Variations in collimator to 
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neck distance, horizontal displacement of the detector and increasing depth of the 
thyroid gland in tissue were shown to affect the accuracy of uptake measurement. A 
depth-based correction for the thyroid gland was derived from the differential counts 
in the x-ray and gamma peaks of 123I. Such an approach could be utilised in clinical 
practice to correct for the depth of the thyroid gland in the neck. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Nuclear medicine 
 
Nuclear medicine is a term that encompasses the use of radiopharmaceuticals for 
both diagnostic and therapeutic applications. The basic premise of a nuclear 
medicine procedure includes the administration of a radiopharmaceutical to either 
induce a therapeutic effect or undertake measurements to glean a diagnostic result. 
Diagnostic applications of nuclear medicine can be further subdivided into those 
concerning imaging, generally using a gamma camera and non-imaging, where in-
vitro or in-vivo assays are conducted on samples or within the body. 
 
The radiopharmaceutical administered principally consists of two chemically 
attached components, the radionuclide and the pharmaceutical. The purpose of the 
radionuclide is, via the process of radioactive decay, to emit ionising radiations to 
administer a therapeutic effect or be detected as part of a diagnostic test. The type of 
ionising radiations emitted from the radionuclide is one aspect of the design of a 
radiopharmaceutical that determines its suitability as either diagnostic or therapeutic. 
Highly ionising particulate emissions, namely α and β particles are principally used 
for therapeutic purposes. Gamma emitting radionuclides are generally reserved for 
diagnostic applications. They are not completely incompatible with the alternative 
use however. For example, 14C is often administered orally for the detection of the 
stomach ulcer causing bacteria, Helicobacter Pylori, and 131I may also be 
administered, although very rarely, for diagnostic thyroid uptake procedures.  As well 
as the emissions, the half-life of the radionuclide will also determine its suitability to 
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be used in a medical context. For diagnostic purposes, the half-life needs to be 
consistent with the length of the investigation but not too long leading to a high 
effective dose or too short to prohibit non-diagnostic data acquisition. 
 
The pharmaceutical element of the radiopharmaceutical determines its fate within 
the body by acting as a tracer for a particular physiologic or biochemical process. 
Some radionuclides may be administered without significant chemical interference. 
For example, 99mTc sodium pertechnetate may be used in its eluted form for 
diagnostic thyroid and Meckel's diverticulum imaging. However, most radionuclides 
will be bound to a pharmaceutical tracer, predominately through the addition of the 
radionuclide to a chemical complex or through incorporation into autologous blood 
cells. Typically, administration of the radiopharmaceutical is via an intravenous 
injection in the antecubital fossa region, however, other modes of administration 
including inhalation and ingestion may be employed depending on the particular 
clinical indication. 
 
Diagnostic imaging using a gamma camera was the predominant nuclear medicine 
procedure undertaken in 2003-2004 (Hart and Wall, 2005). A wide range of 
diagnostic imaging radiopharmaceuticals have been developed to image 
physiological processes of the body. The instrumentation used for nuclear medicine 
imaging was first developed in the 1950s by Hal Anger, an American biophysicist 
(Anger, 1957). The basic components of a gamma camera have not drastically 
changed in the six decades that have proceeded, with the major development being 
the move from analogue to digital image acquisition and processing. A gamma 
camera can provide static, dynamic and three-dimensional reconstructed images of 
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the distribution of a radiopharmaceutical within the body. By virtue of being a 
physiological imaging technique, the acquired images in some instances may not 
closely resemble the anatomical structure of the tissues or organs under 
investigation (Figure 1.1). Hence image fusion with an anatomical imaging modality, 
for example CT or MRI, can be advantageous in some applications. 
 
 
Figure 1.1: Left – 99mTc HDP scan showing accumulation of the radiopharmaceutical 
in the skeletal system. This shows good resemblance with the anatomical structures. 
Right – 99mTc HMPAO scan showing blood perfusion of the brain. Anatomical 
resemblance is more abstract in this instance 
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Non-imaging diagnostic nuclear medicine investigations are either undertaken in-vivo 
(e.g. thyroid uptake assessment) or in vitro (e.g. GFR measurement). There are 
some notable advantages for undertaking non-imaging nuclear medicine 
investigation as compared to imaging using a gamma camera. Firstly, gamma 
camera imaging is inherently an inefficient technique and requires administered 
activities usually in the region of 10s – 100s of MBq of the radionuclide. Non-imaging 
nuclear medicine investigations can employ more sensitive detection equipment and 
therefore the total activity administered to the patient, and hence the radiation 
detriment they receive, can be reduced. The other notable advantage of non-imaging 
techniques is that it is possible to use other radionuclides such as 14C and 125I, where 
their emissions deem them unsuitable for gamma camera imaging. This allows for 
different tracer pathways to be assessed in the body. Some examples of non-
imaging nuclear medicine applications include 75SeHCAT studies to investigate the 
re-absorption of bile acids in the intestines and 51Cr EDTA investigations to calculate 
the GFR of the kidneys as a parameter of kidney function. 
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1.2 Applications of radioiodine in nuclear medicine 
 
Iodine is an essential trace element for human life. One of the primary functions of 
iodine in the body is via the incorporation into thyroid hormones, which allow for the 
regulation of various body processes. The synthesis of thyroid hormones occurs in 
the thyroid gland and therefore dietary iodine is predominately taken up by, and 
stored in, the thyroid.  
 
Radioiodine has been employed in nuclear medicine for both diagnostic and 
therapeutic applications for a number of decades. Only one isotope of iodine is 
stable, namely 127I. The three main medical isotopes of iodine are 123I, 125I and 131I. 
124I, a positron emitter, is also finding some diagnostic clinical application using PET. 
Biologically, radioisotopes of iodine are indistinguishable from 127I when administered 
in unaltered pharmaceutical form. Therefore, administered radioiodine can usually be 
found in high concentrations in the thyroid gland. 
 
The potential detrimental effects of radioiodine accumulation in the thyroid gland 
were evident following the Chernobyl accident. Huge quantities of 131I were released 
into the atmosphere and entered into the human food chain mainly through the cow-
milk pathway. In the subsequent years following the accident, the incidence of 
childhood thyroid cancers, particularity papillary cancer, rose dramatically, in some 
regions to over 100 fold (Stsjazhko et al., 1995). The increase was proportional to 
the radiation dose received (Bennett et al., 2006). 
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In terms of nuclear medicine imaging, 123I is widely used as an imaging radionuclide. 
For diagnostic purposes, the aim is to keep the radiation burden ALARP to prevent 
any stochastic radiation detriment that may occur over time. Although it was once 
commonplace for 131I to be administered for diagnostic purposes, it has generally 
been superseded by 123I. This is due to its convenient gamma emissions for imaging 
and detection using conventional imaging equipment (scintillation or semi-conductor 
detectors) and lower radiation dose to the patient due to the lack of β- emissions. 
Two examples of 123I based investigations not used for thyroid imaging include 123I 
MIBG for neuroendocrine tumour imaging and 123I Ioflupane (DaTscan™) for imaging 
the dopaminergic cells in the brain. Where there is a possibility of free radioiodine, it 
is prudent to administer thyroid blocking medication to reduce the detriment to the 
thyroid for non-thyroid investigations. 
 
Radioiodine treatment is also undertaken for both benign and malignant thyroid 
conditions. 131I is usually employed for both procedures as one of its particulate 
emissions are β- particles. β- particles have a mid level linear energy transfer and can 
therefore cause ionisation over a small distance within tissues (e.g. 1 MeV β- 
particles have a range of less than 1 cm in water (Cherry et al., 2003)). The 
difference between treating a benign and malignant condition usually lies in the fact 
that the patient may have had a thyroidectomy for malignant cancers and the 
administered activities may be in the region of several GBq for malignant therapy as 
opposed to typically 100s of MBq for benign conditions. 
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1.3 Introduction to Monte Carlo simulation 
 
Stochastic simulation techniques have found a wide area of application in a number 
of different fields including the physical sciences, finance, business and 
telecommunications. One of the earliest examples of a stochastic simulation was 
proposed by Comte de Buffon in the 18th Century and is known as the „Buffon needle 
experiment‟. Buffon‟s experiment involved randomly dropping needles on a panelled 
floor to determine the probability that the needle intersects the panels. Monte Carlo 
techniques can also be applied to this experiment to determine an estimate of π. In 
the 1930‟s, Fermi used stochastic methods to study the moderation of neutrons 
(Metropolis, 1987). While working on the Manhattan Project, John Von Neumann 
and Stanislaw Ulam further developed the use of random sampling to solve 
deterministic mathematical equations (Price, 2008). Due to the probabilistic nature of 
the method, the term Monte Carlo was coined as a reference to the famous casino in 
the administrative area and the first paper using this phrase (to describe stochastic 
methods) in the title was published in 1949 (Metropolis and Ulam, 1949).  
 
Monte Carlo simulations allow the collection of a vast amount of information about 
the system that would that in many circumstances not be possible or practical with 
real time experimentation. One particular application of the Monte Carlo method is to 
simulate radiation transport in a given system. The principles of a Monte Carlo 
simulation for radiation transport are outlined by Price (2008) and are summarised as 
follows: 
 A nuclear particle is generated originating from the desired source distribution 
 Sampling routines and cross sectional data is used to determine its fate within 
the specified geometry. 
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 The statistical sampling process relies on the selection of pseudo-random 
numbers and using probabilistic data transport libraries to determine the 
outcome at each step of the particle‟s life. 
 The particle history describes the progression of a particle from the start of its 
simulation to termination. 
 By simulating a sufficiently large number of histories, reliable statistical 
averages of the tallies which are preselected can be returned. 
 
1.4 Current Monte Carlo research in medical physics 
 
The Monte Carlo method has the potential for a wide variety of applications within 
the field of medical physics. The use of Monte Carlo techniques has found particular 
application in radiotherapy treatment planning. A recent review article highlights the 
use of Monte Carlo in radiotherapy treatment planning for both photon and electron 
beams and details some of the commercially available Monte Carlo treatment 
planning systems (Reynaert et al., 2007). It is also envisaged that Monte Carlo 
simulations will be instrumental in the treatment planning for proton beam therapy in 
the near future (Paganetti, 2014). 
 
Its use within nuclear medicine has also been demonstrated for both diagnostic and 
therapeutic applications. An invited perspective article highlights the current uses 
and the future potential of the Monte Carlo method in nuclear medicine (Bolch, 
2010). Some of the current applications highlighted include generating radionuclide 
absorbed dose S values, modelling of therapeutic radiopharmaceutical 
administrations in patients and also the modelling of nuclear medicine diagnostic 
imaging equipment. The design of SPECT and PET systems has received 
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considerable attention with one Monte Carlo code, GATE, written and validated 
specifically, for such applications (Staelens et al., 2003) (Lamare et al., 2006). Also, 
the usefulness of the Monte Carlo method has been demonstrated for radiation 
protection purposes for predicting the dose to nuclear medicine staff members 
wearing different protective garments (Fog and Collins, 2008). 
 
1.5 Outline of research objectives 
 
As previously stated, 123I is a commonly utilised radionuclide for nuclear medicine 
diagnostic imaging and non-imaging investigations. The decay scheme of 123I as 
described in chapter 3 presents particular challenges in terms of accurately 
determining the radioactivity of a 123I based radiopharmaceutical prior to 
administration. In medical institutions, access to sophisticated assay equipment is 
generally not available and therefore for convenience ionisation chambers are 
utilised to undertake the assay. Inaccuracies in determining the radioactivity of a 123I 
based radiopharmaceutical may have two consequences. Firstly, UK legislation 
requires the accurate administration of known amount of activity within particular 
tolerances and therefore compliance with the legislation may be compromised. 
Secondly, inaccuracies in the assay procedures will inevitably propagate into 
uncertainty in quantitative nuclear medicine studies where accurate initial assay is a 
proviso and also semi-quantitative studies, for example thyroid uptake assessment. 
  
Page | 10 
 
The following hypothesis is proposed: 
 
“Monte Carlo techniques can be used to accurately simulate a radionuclide calibrator 
and thyroid uptake counter and quantify uncertainties with respect to 123I 
measurement” 
 
The first element of this work therefore investigates the uncertainties associated with 
123I assay using commonly available assay equipment with suggestions of suitable 
correction strategies. The second theme of the thesis is the investigation of the 
uncertainties associated with thyroid uptake assessments with the application of a 
thyroid depth correction. 
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CHAPTER 2: SIMULATION OF RADIATION TRANSPORT 
USING MONTE CARLO TECHNIQUES 
 
2.1 Introduction 
 
The Monte Carlo method can be used to simulate deterministic processes such as 
the interaction of nuclear particles with matter, using a probabilistic approach. For 
radiation transport, the method is realised by using Monte Carlo radiation transport 
codes. A number of such codes are available, including Monte Carlo N-Particles, 
Electron Gamma Shower and Geant4. 
 
As described in section 1.3, undertaking a simulation does have some distinct 
advantages over experimental studies. For example, Monte Carlo simulations are 
used to assess absorbed doses to tissues that would not be possible to measure 
non-invasively. Also, as shown in later chapters, it is possible to change the material 
compositions of equipment, for example the chamber gas of a radionuclide 
calibrator, which may pose significant cost and practical difficulties if undertaken 
physically.   
 
In this chapter the salient features of Monte Carlo transport codes are presented 
along with an overview of the radiation Monte Carlo code used for the subsequent 
investigations. 
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2.2 Salient features of Monte Carlo radiation transport codes 
 
At the heart of all Monte Carlo radiation transport codes are a number of core 
components to allow for the interactions of ionising radiation with matter to be 
simulated. The simulations outlined in the following chapters of this thesis concern 
photon transport. The following sections are therefore primarily concerned with the 
description of Monte Carlo codes in relation to photon transport. The core 
components as outlined by Price (2008) include: 
 
 Models for the physical processes 
 Sampling routines 
 Tallies 
 Variance reduction techniques 
 
A brief description of each component is provided. 
 
2.2.1 Models for the physical processes 
 
High energy photons (x and gamma rays) may interact with atoms of the materials 
through which they transverse. When a photon interacts with an atom it may undergo 
absorption or scattering events in which it loses a proportion or all of its energy. Any 
energy lost by the incident photon is transferred to the atom. 
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There are four main processes with which photons interact with matter. 
 
 Coherent (Rayleigh) scattering 
 
Coherent scattering is an interaction that occurs when a photon impinges on an atom 
and is scattered without losing any energy. This type of interaction leads to a photon 
being scattered mostly in the forward direction (Ljungberg, 1998). The probability of 
this process increases with decreasing energy (E-1), and increasing atomic number 
of the scattering atom (Z2). Coherent scattering is important at relatively low 
energies, generally less than 50 keV (Cherry et al., 2003).  
 
 Photoelectric effect 
 
In the photoelectric effect an incident photon interacts with an atom, imparting all of 
its energy. A tightly bound inner orbital electron (known as a photoelectron) is 
ejected in the process. An electron from an outer orbit fills the vacancy by falling into 
the inner orbital „hole‟. This results in the emission of a characteristic x-rays 
equivalent to the difference in energy of the two orbital shells. The x-ray is known as 
characteristic because its energy is characteristic of the absorbing material (Brown et 
al., 2001). 
  
The probability of the photoelectric effect is proportional to the cube of the atomic 
number (Z3) and is inversely proportional to cube of the incident photon energy (E-3). 
The photoelectric effect is the predominant interaction in NaI(TI) scintillation crystals 
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(Z=32) used in nuclear medicine and lead (Z=82), a commonly utilised attenuating 
material (Powser and Powser, 2006). 
 
 Compton effect 
 
The Compton effect describes the interaction between a photon and a loosely bound 
orbital electron. A proportion of the photon‟s energy is used to liberate the orbital 
electron from the atom. This results in a decrease of the incident photon energy. The 
energy lost by the incident photon via Compton scattering depends upon the angle 
through which it is scattered and may calculated using Equation 2.1: 
 
)cos1(
111
2
00

cmEE
...Equation 2.1 
 
where E is the Compton scattered photon energy, E0 is the incident photon energy, θ 
is the scattering angle, m0 is the rest mass of the electron and c is the speed of light 
(Brown et al., 2001). 
 
The Compton effect is largely independent of the atomic number of the material and 
is inversely proportional to the energy of the photon (E-1). It therefore predominates 
over the photoelectric effect for low atomic number materials such as soft tissues 
(Z=7.5) (Powser and Powser, 2006). 
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 Pair Production 
 
Pair production is only possible when the energy of the incident photon exceeds the 
combined rest mass of an electron-positron pair (1.022 MeV). In the presence of the 
nucleus, an incident photon may create an electron-positron pair. Any excess photon 
energy is transferred as kinetic energy of the electron and positron and a portion 
may result in an excited nucleus state. High photon energies are required for this 
process to occur, well in excess of the maximum photon energies used for diagnostic 
nuclear medicine. The probability of pair production is proportional to the square of 
the atomic number (Z2). 
 
Figure 2.1 illustrates the predominant interactions based on the incident photon 
energy and atomic number of the material it traverses. 
 
Figure 2.1: Predominant interactions based on the incident photon energy and 
atomic number of the material it traverses (Cherry, 2016) 
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The photon interactions with matter previously described result in a reduction in the 
flux of photons as they pass through the medium. The loss of photons is known as 
attenuation. The attenuation processes for narrow beam photon transport can be 
described by Equation 2.2. 
 
x
x eII
 0 …Equation 2.2 
 
where I0 is the incident intensity of the photons, Ix is the transmitted intensity, μ is the 
linear attenuation coefficient, and x is the thickness of the material.  
 
An integral part of any Monte Carlo code is the ability to model physical interaction 
processes of photons within a material. As previously shown, the likelihood of a 
given interaction is dependent on the energy of the incident photon and the atomic 
number of the material through which it passes. In a Monte Carlo code, this 
information is provided by validated atomic interaction cross-section tables. Photon 
cross-sections for compounds can be provided by a weighted sum of cross-sections 
for the different atomic constituents (Ljungberg, 1998). 
 
The cross-section data are used to create probability density functions which 
describe the likelihood of the physical processes. 
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2.2.2 Random number generator 
 
The probability density functions must be sampled in some way to determine the 
photon‟s behaviour within a material. Sampling is undertaken based on the 
generation of random numbers. A truly random method for generating numbers 
(usually between 0 and 1) is impractical to realise and therefore a computational 
algorithm is adopted. The term pseudo- random number generator is therefore 
applied to computational algorithms for determining random numbers, the most 
common of which is the linear congruental algorithm. This provides a series of 
random numbers based on the initial value (known as the seed) as described by 
Ljungberg (1998): 
 
𝐼𝑛+1 =  𝑎𝐼𝑛 + 𝑏 𝑚𝑜𝑑(2
𝑘)...Equation 2.3 
 
where In is the initial seed value, In+1 is the random number, k is the integer word size 
of the computer and a and b are constants. Normalisation of this integer series of 
random numbers can be undertaken to produce a set of random numbers in the 
range 0 to 1. To ensure a new sequence of numbers different to that produced 
previously requires a different seed value each time. There is also a potential risk 
that the initial seed may be generated in the number sequence; this will therefore 
result in a looping of the numbers generated (Ljungberg, 1998). 
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2.2.3 Sampling routines 
 
Sampling routines are a key requirement for any Monte Carlo code; they are used to 
sample the various probability density functions that describe the photon transport 
and interactions. One such routine, based on the distribution function method, is the 
determination of the photon path length in a material before it undergoes an 
interaction. The probability function is exponential and dependant on both the 
material composition and photon energy (Ljungberg, 1998). For a photon travelling a 
distance of x or less, integrating the distribution yields the following equation: 
 
𝑥 = −
1
𝜇
ln 𝑅 ...Equation 2.4 
 
where R is a random number and µ is the macroscopic linear attenuation coefficient. 
A random number R can therefore be used to sample the path length of the photon 
before an interaction (Rogers and Bielajew, 1986). If the path length to an interaction 
is greater than the path length to a boundary, the photon will be moved to the 
boundary and the process repeated. 
 
2.2.4 Tallies 
 
The main aim of a Monte Carlo simulation is the production of a result, or tallies, 
once the program comes to completion. Tallies are the output a desired parameter 
under investigation in the Monte Carlo simulation. Tallies can be created for a wide 
range of different parameters. Tallies of particular interest to the work presented in 
this thesis include energy deposition in a region and pulse height distribution.  
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2.2.5 Variance reduction techniques 
 
As with any computational simulation technique, the computing time taken to 
complete the simulations to an acceptable level of precision depends on the 
complexity of the modelled geometry and nature of the simulations. Most Monte 
Carlo codes provide some means of precision estimation. One such estimation of the 
precision is the relative error of the mean. The relative error is proportional to the 
inverse square of the number of histories simulated. Therefore a fourfold increase in 
histories will halve the relative error. If the tally in question has a low hit rate, then 
increasing the number of particles simulated is one method of achieving an 
acceptable precision. However, this may mean running the simulation for an 
unacceptably long time as the computing time is proportional to the number of 
particles simulated. Variance reduction techniques are therefore often employed to 
reach an acceptable precision for fewer histories, without distorting the physical 
processes. In the simplest form this may include a cut-off for photons, where photon 
energies lower than the cut-off values are no longer sampled if they will not 
contribute to the tallies. Other methods include geometry splitting, where particles 
entering geometries of importance in the simulation are split to create more particles, 
with the opposite being true for particles entering areas of low importance. Providing 
the tallies are modified by the splitting, this provides a method of increasing the 
histories in the region of interest and therefore reducing the time to reach an 
acceptable precision (X-5 Monte Carlo Team, 2003). 
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2.3 Monte Carlo codes 
 
There are a number of different Monte Carlo codes available either commercially or 
freely distributed using a variety of different platforms. Three of the commonly 
utilised Monte Carlo codes for medical physics applications include MCNP5, EGS 
and Geant4. A brief précis of each code is presented here. 
 
2.3.1 MCNP5 
 
MCNP5 is a general-purpose Monte Carlo transport code that has been publically 
available for the longest period of time (Andreo and Ljungberg, 1998). The 
developers are based at the Los Alamos National Laboratory where some of the 
early work concerning Monte Carlo modelling was undertaken (while developing the 
atomic bomb during World War II). The transport modes that are available are 
photons, neutrons and electrons, which may be used independently or in some 
cases combined. Photon and electron energy ranges of 1 keV to 1000 MeV are used 
to simulate the transport of these particles (X-5 Monte Carlo Team, 2003). MCNP5 
uses ENDF continuous-energy nuclear and atomic data libraries. 
 
To run an MCNP5 program the user creates an input file which is read by the 
program. The user specifies variables such as; 
 
 The geometry of the problem 
 Descriptions of materials including density and atomic numbers 
 Source specifications 
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 Tallies required 
 Variance reduction techniques used to improve efficiency 
 
MCNP5 has been utilised for a wide range of applications. Within medical physics, 
applications include absorbed dose assessments (Reed, 2007) and radiation 
detector design and analysis (Temple, 2007). The MCNP5 webpage hosts a range of 
validation documentation for the transport code (X-5 Monte Carlo Team, 2015). 
Currently, the distribution of MCNP5 is via application to the Radiation Safety 
Information Computational Centre, USA. 
 
2.3.2 EGS 
 
The EGS Monte Carlo code was first developed in the 1970‟s and originated from 
the Stanford Linear Accelerator Centre, USA (Andreo, 1991). Since then, the Monte 
Carlo code has gone through a number of iterations to its current forms. There are 
currently two main subsets of the EGS code that is maintained. EGS5 is maintained 
by the High Energy Accelerator Research Organization, Japan. It is a general 
purpose Monte Carlo simulation package which allows for the coupled transport of 
electrons and photons with energies ranging from a few keV to several hundred GeV 
(Hirayama et al., 2016). The EGS system is written in the MORTRAN computer 
language (Andreo and Ljungberg, 1998). EGSnrc is maintained by the National 
Research Council Canada and has been developed from the EGS4 code, the 
predecessor of both the EGS5 and EGSnrc codes.  The stated coupled electron and 
photon energy ranges for EGSnrc is from 1 keV to 10 GeV (National Research 
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Council, 2015). Both EGS versions are freely available for download (KEK, 2016) 
(National Research Council, 2016). 
 
The EGS Monte Carlo code has been employed for a wide range of medical physics 
problems. The EGSnrc code is distributed with BEAMnrc, which allows for the 
modelling of high energy photon and electron beams from radiotherapy linear 
accelerators and is one of the most popular codes for such applications (Verhaegen 
and Seuntjens, 2003).  EGS5 has also been demonstrated to have particular 
applications for radiation protection. Kato et al. (2011) used EGS5 to calculate the 
personal dose equivalent for positron emitting radionuclides to estimate radiation 
dose. 
 
2.3.3 Geant4 
 
Geant4 is described as “a toolkit for simulating the passage of particles through 
matter” (Agostinelli et al., 2003). The Monte Carlo code has been produced 
collaboratively by a large number of multinational contributors and continues to be 
maintained and developed. In its current form, it is one of the more recently 
developed Monte Carlo codes (1990‟s) compared to EGS and MCNP. It is object 
orientated and implemented in the C++ programming language (Agostinelli et al., 
2003). This allows for additional features to be appended to the code by the user if 
desired. Low energy physics process models for photon transport down to 250 eV 
can be used (Chauvie et al., 2002). The source code is freely available for download 
from the Geant4 internet page along with user documentation (Geant4, 2016).  
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The Geant4 Monte Carlo code has been used for a range of applications including 
high energy physics simulations (e.g. simulating parts of the large hadron collider), 
space and radiation and medical physics (Geant4, 2013). A particular application 
using the underlying structures of Geant4 is GATE. GATE can be used to simulate 
diagnostic nuclear medicine equipment such as SPECT and PET imaging equipment 
(Jan et al., 2004). GATE also allows for the modelling of CT and external beam 
radiotherapy systems (Jan et al., 2011) as well as having potential applications for 
radiation therapy and dosimetry (Sarrut et al., 2014). 
 
2.3.4 Monte Carlo code for subsequent investigations 
 
The previous subsections give a brief introduction to three commonly utilised Monte 
Carlo transport codes for medical physics applications. Each of the Monte Carlo 
codes has stated photon energy ranges that cover the emissions of 123I, which is 
subject to the simulations in this thesis. The purpose of the investigations, consistent 
with the proposed hypothesis, is to assess whether Monte Carlo techniques in 
general are suitable for simulating the uncertainties in 123I assay and thyroid uptake 
measurement. MCNP5 is the code that has been available for the longest period of 
time and is extensively validated (X-5 Monte Carlo Team, 2015). Therefore, of the 
three codes, MCNP5 is used for the subsequent simulations. 
 
Acquisition of the MCNP5 programme was via the Nuclear Energy Agency databank 
(applications to use MCNP5 must now be made to the Radiation Safety Information 
Computational Centre, USA). Simulations were undertaken on Windows™ (Versions 
XP and 10) based PC and laptop platforms.  
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CHAPTER 3: ASSAY OF RADIONUCLIDES 
 
3.1 Introduction 
 
Nuclear Medicine involves the administration of a radiopharmaceutical to a patient. 
The administration of any radioactive medicinal product is governed by the 
appropriate UK legislation. The legislations are designed to protect the patient from 
inappropriate procedures. Prior to any administration, the activity of the 
radiopharmaceutical must be assayed to ascertain the activity is as specified for the 
clinical procedure. The assay is undertaken on a radionuclide calibrator, an 
ionisation chamber designed to measure ionisation currents from radiation 
interactions. 
 
This chapter introduces the legal requirements for the assay of radionuclides in the 
UK. The function of a radionuclide calibrator is then described followed by a 
description of the production and emissions of 123I. Issues regarding the assay of 123I 
are detailed along with currently adopted correction approaches. Finally, the aims of 
this portion of the thesis are outlined. 
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3.2 Legal requirements for accurate assay of radionuclides in the UK 
 
There is a legal requirement in the UK to make an accurate assay of the total 
radioactivity administered to a patient for diagnostic or therapeutic purposes. The 
basis for the corresponding UK legislation stems from the European Union, namely 
the European Directive 97/43/Euratom (The Medical Exposures Directive) (EC, 
1997). The Euratom Directive has been implemented in UK law via The Ionising 
Radiation (Medical Exposure) Regulations 2000 (UK Government, 2000) (as 
amended in 2006 (UK Government, 2006a) and 2011 (UK Government, 2011)). At 
the time of writing, a new Euratom Directive, Council Directive 2013/59/Euratom (EC, 
2013), has been published. The new Euratom Directive must be implemented by 
member states (of which the UK is one) by the 6th February 2018. 
 
The Ionising Radiation (Medical Exposure) Regulations 2000 (IRMER 2000) is 
concerned with medical exposures, occupational health surveillance, health 
screening programmes, medico-legal exposures and medical research. The 
regulations are enforced under the Health and Safety at Work Act 1974 with 
compliance delegated to the Care Quality Commission in England and the devolved 
administrations in Scotland, Wales and Northern Ireland.  
 
IR(ME)R 2000 incorporates the concepts of optimisation and justification for medical 
exposures. An exposure may be justified if there is a net benefit to the patient from 
the exposure. The objective of the exposure, potential diagnostic or therapeutic 
benefits, detrimental effects and alternative techniques must be considered. In 
essence, justification is a cognitive process which is undertaken by the practitioner, 
an individual identified in IRMER 2000. In the particular case of nuclear medicine, 
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the ARSAC notes for guidance specify that the practitioner should be a doctor or 
dentist in possession of a certificate issued by the Secretary of State for Health in 
accordance with The Medicines (Administration of Radioactive Substances) 
Regulations 1978 (UK Government, 1978) (as amended 1995 (UK Government, 
1995) and 2006 (UK Government, 2006b)).  
 
The optimisation of exposures requires that the radiation detriment received by a 
patient is kept ALARP. For nuclear medicine procedures the detriment is typically 
quantified in terms of effective dose. Compliance with ALARP requires a 
multifactorial approach and depends on variables such as the radionuclide, the 
pharmaceutical, the age of the patient and the equipment used. One of the key 
factors in determining the radiation detriment to the patient and complying with the 
principles of ALARP is the activity of the radionuclide used for the investigation or 
therapy. The rate of radioactive decay, defined in terms of disintegrations per second 
(S.I. unit Bq), determines the rate of emission of ionising radiations. The higher the 
rate of emission, the more likely there will be an ionising interaction, which may 
result in a stochastic effect. 
 
ARSAC through its notes for guidance recommends an appropriate activity to be 
administered for a given clinical investigation (ARSAC, 2016). The recommendations 
are based on scientific evidence relating the administered activity and image quality. 
The notes for guidance specify an upper recommendation of administered activity 
that is considered appropriate for a given diagnostic investigation. Under certain 
circumstances, exceeding this may be justified, for example, in patients with a high 
body mass index where the diagnostic quality of the image may be compromised 
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without a higher administered activity. The IRMER 2000 legalisation requires the 
documentation of local diagnostic reference levels. For nuclear medicine, this would 
be the activity administered to a patient for a given clinical investigation with 
reference to the ARSAC recommended activities. Once a diagnostic reference level 
has been specified, a tolerance of ±10% is acceptable for diagnostic procedures and 
±5% for therapeutic procedures. The tolerances are applied to reflect uncertainties in 
the assay procedure and the inherent difficulties in providing radiopharmaceuticals to 
high precision (assuming an accurate calibration). Therefore, accurate assay of a 
radionuclide is critical in ensuring that the legislative requirements for ALARP can be 
realised. 
 
3.3 Assay methodology 
 
Primary techniques for the standardisation of radionuclide activity are held by the 
NPL in Teddington, UK. A number of instruments are employed to undertake the 
primary standardisation measurement. Typically, a radioactive sample is assayed 
using one of the primary techniques (e.g. coincidence counting) to determine the 
specific activity in the sample, expressed in terms of Bq g-1, along with an associated 
measurement uncertainty. To ensure international standardisation of radionuclide 
sources, NPL works with other international metrological institutes to certify the 
primary standardisation techniques are comparable (NPL, 2015a). However, these 
primary techniques are complex, time consuming and expensive to administer. 
Therefore once a radionuclide has been assayed, it is used to calibrate secondary 
standard instruments or provide secondary standard sources for dissemination to 
end users. The secondary standard instruments are typically ionisation chambers 
suitable for the assay of radioactivity in vials or syringes. A typical calibration of a 
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secondary instrument would be as follows. Once the activity concentration of the 
sample is known, it is transferred to a secondary instrument in a standard container 
and volume. The ionisation current is measured and knowing the activity of the 
sample, a calibration factor can be derived to convert current to activity (Baker, 
2005). 
 
The basic components of an ionisation chamber consist of a sealed gas chamber, 
electrodes, electrometer, and display device (Figure 3.1). The gas is usually kept at 
a pressure several times that of the ambient atmospheric pressure (Gadd et al., 
2006). The sealing of the chamber ensures that there are no variations in gas 
density that may have an adverse effect on the calibration. Furthermore, keeping the 
pressure of the gas somewhat higher than ambient pressure increases the linear 
attenuation coefficient for radiation interaction. 
 
 
Figure 3.1: Schematic of a radionuclide calibrator (IAEA, 2015)  
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When a radioactive sample is placed within the chamber, some radioactive 
emissions may pass through the chamber wall and cause ionisation of the gas. 
Within the chamber there are also two electrodes kept at a potential difference of 
~100 – 1000 V. The purpose of the electrodes is to collect the positive and negative 
ions created by the ionisation of the gas. The correct choice of potential difference 
between the electrodes is important to ensure that it is high enough to prevent 
recombination of the positive and negative ions, but insufficient to create further 
ionisation through acceleration of the arising ions. This ensures that there is a direct 
proportionality between the ionisation current induced and the energy deposited via 
ionisation in the chamber. The ionisation current generated is usually of the order of 
pA for medical radionuclide assay but a range of currents from pA to µA may be 
induced. A single electrometer may not be able to accommodate such a current 
range and so a number of electrometers may be employed for measurement, with 
electronics used to switch between them. Once the current is measured, a 
calibration factor must be selected to ensure that the measured current is properly 
converted to the activity for the particular radionuclide assayed. The calibration factor 
depends on several variables, with one of the primary variables being the energy of 
the radionuclide emissions. After the application of the calibration factor, the display 
unit is configured to display the activity in an appropriate unit. 
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A typical range of displayed activity units in nuclear medicine would be GBq to kBq. 
Measurement of activities lower than the order of kBq will suffer from high statistical 
variations due to the poor sensitivity of the electrometers to measure low ionisation 
currents. In such circumstances, a radionuclide calibrator would not be the ideal 
measurement device and an alternative detection system, such as a NaI(Tl) or 
HPGe detector would be more appropriate, provided that associated standard 
sources are available. Activities much greater than the order of GBq can be assayed 
on a radionuclide calibrator, but the lack of requirement for such activities in a 
medical context and the associated radiation protection issues makes this activity 
redundant. 
 
The secondary standard instrument held by NPL is known as the Fidelis Secondary 
Standard Radionuclide Calibrator (Figure 3.2). The Fidelis comprises the NPL-
designed nitrogen filled ionisation chamber and an electrometer and user interface 
unit from Southern Scientific Ltd. (NPL, 2015b). The Fidelis is provided with a 
database of traceable calibration factors to the NPL primary standardisations. Each 
calibration factor can be retrieved by the display software when a particular 
radionuclide, container and volume are selected. A number of Fidelis calibrators 
have been built to the same specification as the master Fidelis chamber held at NPL 
and are available for purchase by nuclear medicine or other departments. 
  
Page | 31 
 
 
Figure 3.2: Fidelis secondary standard radionuclide calibrator (NPL, 2015b) 
 
Before installation at the department, the chamber is checked against the master 
chamber at NPL to ensure that the responses are equivalent. This ensures that for 
the factor database generated for the master chamber is applicable to other Fidelis 
chambers. The factor database is editable by the user, which allows the addition of 
new calibration factors when they are published by NPL (available from the NPL 
website (NPL, 2015c)). Caution must always be exercised when editing the database 
to ensure typographical errors are not introduced which may comprise the validity of 
the calibration factors. Periodically, a new database may be disseminated by NPL to 
Fidelis users. Once disseminated into nuclear medicine departments, the Fidelis 
chambers provide a means of assay traceability to the primary methods for 
standardisation. 
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The Fidelis is relatively expensive and is not an instrument of choice for the routine 
assay of radionuclides in a nuclear medicine department. For example, a regional 
medical physics department may have one Fidelis calibrator but may need 10 – 20 
for routine radionuclide assay. In this case, field radionuclide calibrators are 
employed. Field instruments are produced by a number of manufacturers including 
Capintec, Biodex, Veenstra and PTW. Again, the basic design of the calibrators is 
consistent with that previously described. There may also be subtleties in the 
dimensions of and the materials used for each of the manufacturers calibrators. 
 
One of the main differences between the Fidelis and a field instrument is the number 
of available calibration factors for the user to select. Generally, a field calibrator will 
have one factor for a given radionuclide.  
 
Calibration factors will have been generated from measurements in a particular 
container and volume [consideration throughout is only given for radionuclide 
solutions]. However, calibration is dependant not only on the emissions, but also on 
the container material, the geometry of the container and also the volume of the 
solution. Such variables and their impact on the calibration of a radionuclide 
calibrator are discussed in detail in the NPL Measurement Good Practice Guide No. 
93: Protocol for Establishing and Maintaining the Calibration of Medical Radionuclide 
Calibrators and their Quality Control (Gadd et al., 2006). The Fidelis has a number of 
container and volume combinations. To ensure that the field chamber is accurate for 
different containers and volumes, inter-comparison exercises must be undertaken to 
cross-calibrate the Fidelis against a field chamber. This would consist of taking a 
radioactive sample, measuring it in the Fidelis chamber and then measuring it in the 
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field chamber. A comparison of measurements, appropriately decay corrected, will 
yield a ratio of the Fidelis to field chamber measurement. This may then be the basis 
of implementing a new calibration factor or the introduction of a correction for an 
existing calibration factor. 
 
3.4 123I production 
 
The predominant mode of production of 123I is using a cyclotron (Guhlke et al., 2007). 
There are two main cyclotron routes to producing 123I following proton, deuteron or 
helium irradiation, either directly or via the intermediate production of 123Xe. The first 
two production modes in Table 3.1 show the nuclear reactions involving 123Xe (IAEA, 
2009). Both of the xenon-123 routes can produce high purity 123I as the 123Xe can be 
chemically separated from the target material and allowed to decay to 123I. However, 
as can be seen from Table 3.1, this route does require large irradiation energies, 
generally only achievable by cyclotrons located in large research facilities. The most 
commonly adopted route of 123I production is via the 124Te(p, 2n)123I reaction by 
irradiating high purity 124Te with protons (IAEA, 2009). Following irradiation, the 123I is 
chemically extracted from the target material. Figure 3.3 shows the excitation 
function for the 124Te(p, 2n)123I reaction. The notable advantage of this production 
route is that much lower cyclotron energies may be employed for the reaction. This is 
more suitable for industrial level production cyclotrons found in commercial 
production facilities (Guhlke et al., 2007). However, 125Te impurities in the target 
material will result in the production of 124I via the 125Te(p, 2n)124I reaction. Their 
abundance at production is low compared to the total 123I activity. However, because 
of the longer half-life of 124I (4.2 days) compared to 123I (13.2 hours), the proportion of 
the impurity increases over time. 
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Nuclear reaction 
Useful energy range 
(MeV) 
Natural abundance of 
target material (%) 
127I(p, 5n)123Xe:123I 55+ 100 
127I(d, 6n)123Xe:123I 83 100 
122Te(d, n)123I 14–8 2.4 
123Te(p, n)123I 15–8 0.87 
124Te(p, 2n)123I 26–20 4.6 
124Xe(p, pn)123Xe:123I 15–30 0.10 
121Sb(4He, 2n)123I 15–25 57.4 
123Sb(3He, 3n)123I 20–30 42.6 
Table 3.1: Nuclear reactions to produce 123I (IAEA, 2009) 
 
 
Figure 3.3: Excitation function for the 124Te(p, 2n)123I reaction (IAEA, 2009) 
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3.5 123I decay scheme 
 
The routine assay of 123I poses particular problems. Clarification of this statement 
requires a detailed analysis of the decay scheme and the principal energies and 
emission probabilities of 123I as seen in Figure 3.4 and Table 3.2. 
 
 
Figure 3.4: Decay scheme for 123I (ORAU, 2015) 
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Radiations 
 
y(i) 
 
E(i) 
 
y(i)×E(i) 
 (Bq-s)
-1
 (MeV) 
gamma 1 
 
8.28×10
-01
 
 
1.590×10
-01
 
 
1.32×10
-01
 
 
ce-K, gamma 1 1.35×10
-01
 
 
1.272×10
-01
 
 
1.72×10
-02
 
 
ce-L, gamma 1 1.60×10
-02
 
 
1.540×10
-01
 
 
2.47×10
-03
 
 
ce-M, gamma 1 3.46×10
-03
 
 
1.582×10
-01
 
 
5.48×10
-04
 
 
ce-N+, gamma 1 8.27×10
-04
 
 
1.590×10
-01
 
 
1.32×10
-04
 
 
gamma 9 
 
7.07×10
-04
 
 
2.480×10
-01
 
 
1.75×10
-04
 
 
gamma 12 7.86×10
-04
 
 
2.810×10
-01
 
 
2.21×10
-04
 
 
gamma 18 1.25×10
-03
 
 
3.463×10
-01
 
 
4.33×10
-04
 
 
gamma 21 4.25×10
-03
 
 
4.400×10
-01
 
 
1.87×10
-03
 
 
gamma 23 3.14×10
-03
 
 
5.053×10
-01
 
 
1.59×10
-03
 
 
gamma 24 1.38×10
-02
 
 
5.290×10
-01
 
 
7.31×10
-03
 
 
gamma 25 3.79×10
-03
 
 
5.385×10
-01
 
 
2.04×10
-03
 
 
gamma 31 8.28×10
-04
 
 
6.246×10
-01
 
 
5.17×10
-04
 
 
gamma 33 2.66×10
-04
 
 
6.879×10
-01
 
 
1.83×10
-04
 
 
gamma 34 6.12×10
-04
 
 
7.358×10
-01
 
 
4.50×10
-04
 
 
gamma 35 5.90×10
-04
 
 
7.836×10
-01
 
 
4.62×10
-04
 
 
Kalpha1 X-ray 4.58×10
-01
 
 
2.747×10
-02
 
 
1.26×10
-02
 
 
Kalpha2 X-ray 2.46×10
-01
 
 
2.720×10
-02
 
 
6.70×10
-03
 
 
Kbeta1 X-ray 8.66×10
-01
 
 
3.100×10
-02
 
  
2.69×10
-03
 
 
Kbeta2 X-ray 
 
2.66×10
-02
 
 
3.171×10
-02
 
  
8.43×10
-04
 
 
Kbeta3 X-ray 
 
4.46×10
-02
 
 
3.094×10
-02
 
  
1.38×10
-04
 
 
Auger-LMX 
 
3.11×10
-01
 
 
3.849×10
-03
 * 
 
1.20×10
-03
 
 
         Listed X, gamma, and gamma
±
 Radiations 
 
1.71×10
-01
 
 
Omitted X, gamma, and gamma
±
 Radiations** 
 
6.76×10
-04
 
 
Listed beta, ce, and Auger Radiations 
 
2.80×10
-02
 
 
Omitted beta, ce, and Auger Radiations** 
 
1.21×10
-04
 
 
Listed Radiations 
 
1.99×10
-01
 
 
Omitted Radiations** 
 
7.97×10
-04
 
 
*   Average Energy (MeV). 
a
   Maximum Energy (MeV) for subshell. 
** Each omitted transition contributes <0.100% to Sum of y(i)×E(i). 
Table 3.2: Emissions of 123I (ICRP, 1983). Y(i) is the yield per disintegration, E(i) is 
the energy of the emission, y(i)×E(i) is the sum of the yield and the energy of the 
disintegration and ce are conversion electrons 
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123I decays 100% via electron capture to 123Te which is a stable nuclide. The 
principal gamma energy (gamma 1) is 159 keV. For diagnostic nuclear medicine 
purposes, this is the gamma photon that is used for detection as it falls within the 80 
– 400 keV range, which is ideal for detection using a NaI(Tl) scintillation crystal. 
There are a number of other gamma emissions in the decay scheme. They are 
generally at a higher energy than the principal gamma emission but notably at a 
much reduced yield, typically 100-1000 times less abundant as compared to gamma 
1. The decay of 123I is also characterised by the emissions of K-alpha and K-beta 
characteristic x-rays at energies ranging from 27 – 31 keV with a combined 
abundance of 86.2%. 
 
3.6 Uncertainties associated with 123I assay 
 
Field radionuclide calibrators generally only provide one calibration factor, typically 
for a standard glass vial, for any given radionuclide. The decay scheme for 123I has 
been shown to present particular problems for the accurate assay of a sample of this 
radionuclide. The difficulty in accurately assaying a sample of 123I primarily stems 
from the emissions associated with the characteristic x-rays. 
 
Wiarda (1984) identified that a large portion of characteristic photons are absorbed in 
a glass vial due to a increase in the mass attenuation of glass towards low energy 
photons at around 30 keV. Wiarda (1984) also showed that up to 80% of the total 
response from 123I is due to the characteristic x-rays. However, the type of 
radionuclide calibrator and specifications of the vials were not disclosed. In a paper 
published the same year, Harris et al. (1984) reported similar findings, in that up to 
70% of the chamber response was due to the characteristic x-rays. The authors 
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identified their radionuclide calibrator as a argon filled Capintec CRC-5. In a more 
recent paper, Tyler and Woods (2003) reported a difference in chamber response of 
up to 60% between a P6 vial and a 5ml syringe. This response was documented for 
an argon filled ARC 120 calibrator. Thompson et al. (1997) also described 
experiences at their centre where there was a large variation in readings compared 
to the expected values. Vials tended to read 25% below the expected value and 
syringes tended to read 27% higher than the expected value. 
 
It is clear from previous publications that the assay of 123I is problematic, particularly 
when moving from a glass vial to a syringe. The degree of variation in measurement 
may not only depend on the type of material used to house the radionuclide but also 
the particulars of the radionuclide calibrator design and material composition. 
Manufacturers predominately calibrate their radionuclide calibrators for a standard 
vial. However, once dispensed, the activity is usually measured in a syringe. The 
assay of 123I in a syringe on a radionuclide calibrator with a factor specified for a vial 
could potentially result in an overestimation of the activity in the syringe in the region 
of 60% - 80%. Such an overestimation would mean that the patient would receive 
less than half of the prescribed activity. This may have a detrimental effect on the 
image quality or the ability to achieve a diagnostically reliable result. Repeated 
investigations may actually result in a higher radiation detriment than otherwise 
would have been received. 
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To ensure an accurate assay of 123I, the options for a field radionuclide calibrator are 
to use an individually derived calibration factor for each container, a individually 
derived multiplicative correction factor for each container or a filtering system 
designed to negate the effects of the characteristic x-rays.  
 
The first two options can be undertaken using the following process. Firstly, a 
homogenous stock solution of 123I can be produced in a volume larger than all the 
samples required for measurement. A standard volume of the solution can be 
dispensed into a glass vial for which the calibrator has a traceable calibration factor. 
This sample is assayed in the calibrator using this factor to determine the activity 
concentration of the solution. Further samples can then be sub-dispensed from the 
stock solution into the various syringes and other containers that are used clinically. 
As the activity in each syringe can be calculated from the volume dispensed, 
individual calibration factors can be derived for each container, or a correction factor 
derived with respect to the reading made on the vial calibration setting. One of the 
main issues with such a process is that there are a large number of different syringe 
and volume combinations to consider when undertaking such an exercise. The result 
is there are also a large number of calibration factors or correction factors to 
consider. This may lead to the potential for the wrong calibration or correction factors 
being selected. 
 
The third option, the use of a filtering system, is one that has been investigated in the 
literature. The principle of a filtering system is to use an absorbing material to 
selectively attenuate the low energy characteristic x-rays while permitting a 
measureable portion of the main gamma radiation to transmit to the radionuclide 
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calibrator. One of the first examples of use of such a material was documented by 
Wiarda (1984). Wiarda (1984) used a copper filter of thickness 1 mm and placed 
sources containing 123I, 127Xe or 133Xe into the well of a radionuclide calibrator. 
Measurements demonstrated a significant reduction in the characteristic x-ray peak 
while allowing 93% of the 159 keV gammas to pass through. Since this time, the use 
of a copper filter has found widespread application for not only the assay of 123I but 
also for 111In. Kowalsky and Johnson (1998) undertook some practical work with 125I 
as a mock radionuclide for 123I to determine the optimal thickness of a copper filter. 
They found that the transmission of the x-rays fell below 1% when using a copper 
thickness of 0.6 mm. Harris et al. (1984) also showed that thicknesses of copper of 
the order of 0.5 mm was sufficient to reduce penetration of the x-rays to less than 
1%. Kowalsky and Johnson (1998) also specifically looked at the activity variations 
with 1 ml, 3 ml and 10 ml syringes and a 10 ml vial for an argon filled Capintec 
calibrator. For the same volume, they found that the largest variation of 44% was 
seen when comparing a 1 ml syringe with the manufacturers recommended 
calibration factor. When using 0.64 mm of copper, the variation in activity measured 
in all containers decreased to below 3%. 
 
From a practical perspective, the use of a filtering system such as copper has some 
distinct advantages over the use of individual calibration factors. A single factor can 
be determined that allows assay of all material types. From the current literature, 
those calibrators identified typically were argon filled field chambers. 
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Monte Carlo models for a radionuclide calibrator have been described in the 
literature previously. Laedermann et al. (2004) undertook a Monte Carlo simulation 
using GEANT 3 of an argon filled Veenstra VDC-405 radionuclide calibrator. The 
authors were able to reproduce the response of the detector and validate their 
results against practical measurements. Olsovcová (2010) undertook a Monte Carlo 
simulation of an argon filled radionuclide claibrator with vial and syringe geometries 
containing 111In, 123I and 153Sm. The author was able to estimate uncertainties for this 
particular chamber when assaying with a vial and syringe and determined an 
appropriate copper filter thickness for correction. 
 
3.7 Aims of Monte Carlo radionuclide calibrator simulations 
 
The influence of a copper filter to differentiate the characteristic x-rays on a nitrogen 
filled NPL chamber has not been investigated. Furthermore, calibration factors for 
syringes do not appear in the official list of approved calibration factors published by 
NPL (NPL, 2015c). Syringe calibration factors for the NPL secondary standard 
calibrator have been previously published (Tyler and Woods, 2003) and are detailed 
in a NPL report (Tyler and Woods, 2002). However, users of Fidelis calibrators were 
notified via private correspondence that the syringe calibration factors were placed 
under review in 2008 and should not be used. Furthermore, additional 
correspondence with NPL in 2016 indicated that syringe calibration factors are 
unlikely to be included in any forthcoming Fidelis database dissemination. 
Investigating 123I assay using the NPL nitrogen filled Fidelis calibrator forms the basis 
of the initial Monte Carlo simulations. 
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CHAPTER 4: MONTE CARLO SIMULATION OF A FIDELIS 
RADIONUCLIDE CALIBRATOR 
 
4.1 Introduction 
 
In the previous chapter the aims of the initial investigations were outlined to 
encompass the Monte Carlo modelling of a Fidelis radionuclide calibrator. In this 
chapter the performance specifications of a Fidelis radionuclide calibrator are 
outlined and assessments undertaken to ascertain current performance. The 
material and geometric compositions of the Fidelis radionuclide calibrator are 
detailed and a Monte Carlo model of the Fidelis was created. Initial simulations were 
undertaken to produce a sensitivity curve to characterise the performance of the 
Fidelis. Finally, validation of the Monte Carlo model was undertaken for a selection of 
radionuclides via comparison with the published NPL calibration factors. 
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4.2 Fidelis secondary standard calibrator performance specifications 
 
The Fidelis is manufactured by Southern Scientific Ltd. and comprises a well type 
ionisation chamber connected to a laptop computer with associated software. The 
chamber is the same as the NPL calibrator type 271 described by Woods et al. 
(1983). In the paper the authors describe the requirements for which the calibrator 
was designed: 
 
 Traceability to NPL national standards of radioactivity 
 Separate and universally interchangeable ionisation chamber and 
electrometer modules 
 Ionisation chamber to have the same calibration figures within ±0.2% for 60Co, 
±1% for 57Co and ±6% for 125I 
 Response to be independent of pressure and temperature variations 
 Maximum error due to saturation losses for 10 GBq of 99mTc to be not greater 
than 1% 
 Accuracy of current measurement to be within ±1% for currents greater than 
1pA 
 
The Fidelis is a sealed, concentric cylinder type of calibrator and it is predominantly 
constructed of aluminium alloy. The chamber is filled with dry nitrogen to a pressure 
of 1 MPa. A polarising voltage of 1450 V is applied between the cathode and anode 
within the chamber (Woods et al., 1983). The electrometer integrated into the base 
of the chamber is the „new state-of-the-art, high resolution, Pam Electrometer 
module‟ with a documented linearity to within ±1% (Southern Scientific Ltd., 2009). 
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A key parameter of a radionuclide calibrator is that the chamber is linear over a wide 
range of activity. This is particularly important when comparing measurements with 
Monte Carlo simulation, which is not subject to linearity issues due to sequential 
particle sampling. Woods et al. (1983) demonstrated that the chamber was linear up 
to an activity of 100 GBq of 99mTc (only 1% current loss observed). This value is 
generally in excess of what would be assayed for administered activities. 
 
Woods et al. (1983) also demonstrated good reproducibility between different type-
matched chambers. Reproducibility is an important factor in ensuring that calibration 
factors derived for the primary chamber are equally applicable to other type-matched 
chambers. 
 
The Medical Physics Department at the University Hospital of Wales purchased a 
Fidelis system in 2009 (S/N 06049). When comparing a Monte Carlo model with 
Fidelis performance, it is important to ensure that the chamber is operating within its 
specified tolerances. This is particularly pertinent if the Monte Carlo model is used to 
derive new calibration factors. In terms of ensuring a good correlation between the 
Monte Carlo model and the physical system, the main performance characteristics 
include accuracy of the calibration factors (which relates to reproducibility between 
chambers) and activity linearity. These performance characteristics are considered in 
turn. 
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4.3 Reproducibility of the Fidelis 
 
Before purchase, the Fidelis chamber was checked against the master chamber at 
NPL to ensure the response of the instrument was within specification. Five 
radioactive sources were assayed in the chamber and compared with the NPL 
master chamber. The ratio of the current measurements must be within the 
compliance ratio as specified in Table 4.1. The variation in current measurements 
was also checked between the NPL electronics and the Fidelis electronics. As can 
be seen by the results in Table 4.1, the specification was met or exceeded in all 
cases. 
 
Radionuclide 
Compliance 
ratio 
requirements 
Test chamber 
current/standard 
chamber current 
Expanded 
uncertainty 
% difference between test 
chamber current 
measurements using NPL 
and Fidelis electronics 
125
I 0.96 – 1.04 0.9933 ±0.0087 -0.36% 
241
Am N/A 1.00265 ±0.0029 -0.45% 
57
Co 0.99 – 1.01 1.0076 ±0.0030 -0.51% 
137
Cs N/A 1.0005 ±0.0029 -1.03% 
60
Co 0.997 – 1.003 1.0000 ±0.0029 -0.50% 
Table 4.1:  Acceptance test results for the Fidelis S/N 06049 
 
Continued assurance that the Fidelis is stable was provided by routine quality control 
protocols. The Fidelis has an in-built quality control routine that assess the amplifier 
offset, ambient background radiation levels and high voltage values. In addition, the 
response of the calibrator is checked using a 10 MBq 137Cs sealed source, which 
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was initially assayed on the chamber by NPL. The constancy of the chamber 
response for the sealed source was assessed and has remained predominately 
within the specified tolerance of ±2% since purchase. 
 
4.4 Accuracy of the Fidelis calibration factors 
 
The calibration factors for each radionuclide and container combination are 
expressed in terms of the ionisation current (pA) per MBq of activity and are 
published on the NPL website (NPL, 2015c). Each calibration factor is published 
along with an associated uncertainty. For a P6 or Schott vial, the calibration factors 
issued by NPL are 1.685 pA/MBq ± 0.84% and 1.721 pA/MBq ± 0.90% respectively 
for 4 ml of 123I.  
 
A national inter-comparison exercise to assess the accuracy of hospital radionuclide 
calibrators for 123I was conducted by NPL in November 2015. The Medical Physics 
Department at the University Hospital of Wales participated in the inter-comparison. 
Each department was issued with a Schott vial containing 4 ml of an 123I solution. 
The solution was assayed using a number of field calibrators in the Department and 
also using the Fidelis. Following measurement and return of the results, a provisional 
vial activity value has been provided by NPL. The provisional results for the assay of 
a Schott vial containing 4 ml of 123I (calibration factor 1.721 pA/MBq) are summarised 
in Table 4.2. The results show that the Fidelis is accurate to within +0.8% for an 123I 
measurement in a Schott vial. As the calibration factors are within 2.2% for a Schott 
vial and a P6 vial, the implication is that a similar accuracy would be achieved with a 
P6 vial. 
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Fidelis 
measurement 
time 
Fidelis 
reading 
(MBq) 
Decay corrected 
activity to 
reference time 
(MBq) 
Average 
activity 
(MBq) 
% difference between NPL 
measured activity and 
Fidelis measured activity 
11/11/2015 
14:39 
105.9 104.0 103.9 0.75% 
11/11/2015 
14:39 
105.8 103.9   
11/11/2015 
14:39 
105.8 103.9   
Table 4.2: Results from a national inter-comparison exercise for 123I undertaken in 
November 2015. The results show a less than 1% variation in the response of the 
Fidelis chamber compared to the national standard measurements and within the 
accuracy uncertainty stated for the calibration factor 
 
4.5 Activity linearity of the Fidelis 
 
An activity linearity assessment was undertaken using an elution vial containing a 10 
ml solution of 99mTc with an initial activity of 12 GBq. The vial was placed in the well 
of the chamber and the Fidelis software used to log activity measurements every 100 
seconds over the course of 65 hours. 
 
Figure 4.1 shows the decay of the 99mTc sample over the duration of the 
assessment. As expected, the curve indicates exponentially decreasing activity. 
 
Figure 4.2 shows the natural logarithm of the measured activity against time. The 
gradient of the linear best fit line corresponds to the decay constant for 99mTc. From 
this the half-life may be derived.  
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The half-life was calculated to be 6.025 hours, +0.3% from the expected value of 
6.007 hours (Chiste et al., 2004). Acceptable linearity tolerances are specified in the 
NPL Measurement Good Practice Guide No. 93 (Gadd et al., 2006). The tolerance 
specified by Gadd et al. (2006) for a reference instrument is ±1%. The Fidelis also 
does not display any significant electrometer range changing discrepancies, which 
can result in errors when assaying either side of electrometer auto-ranging.  This 
therefore means that the Fidelis is performing within the expected linearity tolerance 
over a wide range of activity.  
 
 
Figure 4.1: Fidelis decay curve for 99mTc 
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Figure 4.2: Determination of the half-life is achieved by using the decay constant as 
specified as the gradient of the straight line fit 
 
4.6 Geometric structure of the Fidelis 
 
Monte Carlo modelling of the Fidelis requires detailed knowledge of the materials 
and geometries of the system. Access to such information is commercially sensitive 
and therefore estimations have been made where appropriate. 
 
The main component of the Fidelis that can be modelled is the chamber. The 
particulars of the electrometer are not important from a modelling perspective, as 
previously shown, the Fidelis displays activity linearity within the required 
specification. 
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The basic components of the chamber are the inner tube, outer tube, electrode, base 
and top. The dimensions of the various components are detailed in Table 4.3. The 
Fidelis has various connections from the electrode to the electrometer that are not 
replicated in the model. These additional connections represent a small total area of 
the sensitive volume under investigation and their effect is assumed to be negligible 
from a modelling perspective. As can be seen, each of the core components can be 
modelled as a series of cylindrical objects. 
 
Component 
Length 
(cm) 
Diameter 
(cm) 
Thickness 
(cm) 
Inner tube 37.8 7.5 0.1 
Outer Tube 36 19 0.25 
Electrode 30 13 0.1 
Base 1.9 19 0.1 
Top 1.4 19 0.1 
Table 4.3: Dimensions of the core components of the Fidelis chamber 
 
The two other aspects of the Fidelis that require modelling are the jig and radioactive 
sample containers. The jigs are designed to ensure reproducible positioning of the 
sample container within the well of the chamber. Three jigs were supplied with the 
Fidelis, one for a 10 ml P6 vial, one for a 10 ml Schott vial and a jig for capsules. No 
jigs for the reproducible positioning of syringes within the chamber were supplied.  
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The validation was undertaken using the P6 jig supplied with the calibrator and a 
radionuclide solution within a P6 vial.  The P6 jig has an internal diameter of 5.6 cm 
and a length from the base of the holder to the top of 21 cm. The internal diameter of 
the opening at the top of the P6 vial is taken to be 1.275 cm. The thickness of the 
main body of the vial is taken to be 0.12 cm. 
 
4.7 Material composition of the Fidelis 
 
Specifications for the materials were supplied by NPL and the manufacturers of P6 
vials. The Fidelis chamber is primarily constructed of aluminium alloys as specified in 
the appropriate BS. Table 4.4 shows the material composition of the chamber 
(current BS is also noted). 
  
Element Top and Bottom Outer Tube Inner Tube Electrode 
 
BS 1470 NS4 H6 
(5251) 
BS 1471 HT30 
(6082) 
BS 1471 HT9 
(6063) 
BS 1470 S1B 
Aluminium 96.7 97.15 97.65 99.5 
Silicon 0.4 0.7 0.2 0.15 
Iron 0.5 0.5 0.5 0.15 
Copper 0.15 0.1 0.1 0.05 
Manganese 0.1 0.4 0.4 0.05 
Magnesium 1.7 0.6 0.6 - 
Chromium 0.15 0.25 0.25 - 
Zinc 0.15 0.2 0.2 0.1 
Titanium 0.15 0.1 0.1 - 
Density 
(g cm-3) 
2.69 2.70 2.70 2.71 
Table 4.4: Table of materials 
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The inner containment of the calibrator is filled with nitrogen gas to a pressure of 1 
MPa. The Monte Carlo simulation requires materials to be specified in terms of 
density as opposed to pressure. The density of a gas can be calculated using the 
relationship: 
 
P = R × ρ × T....Equation 4.1 
 
where P is the pressure (Pa), R is the individual gas constant (J kg-1 K-1), ρ is the 
density (kg m-3) and T is the temperature of the gas (K). Taking the pressure to be 1 
MPa, the individual gas constant as 296.8 J kg-1 and the temperature as 294 K 
(taken to be 21 °C), the density of the nitrogen gas is calculated to be 0.01146          
g cm-3. This value is approximately ten times higher than the normal atmospheric 
density.  
 
The P6 jig is modelled as PMMA with a density of 1.19 g cm-3 and the P6 vial is 
modelled as glass with a density of 2.40 g cm-3. 
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4.8 Monte Carlo Fidelis model 
 
The basic format of an MCNP5 input file consists of a text file composing the cell 
cards, surface cards, material cards and source definition. A detailed description of 
the MCNP5 input file for the Fidelis is provided in this section. 
 
4.8.1 Cell card 
 
The first section in the MCNP5 input file (cell cards) describes the cell information 
within the geometry. 
 
 
 
In the above example there are 11 separate cells that make up the geometry. The 
first column details the cell numbers, 2 through to 12. The second column details the 
material number that will be ascribed to the cell in the model. The materials are 
defined later in the input file. The third column details the density of the cell.  A minus 
sign in front of the density value indicates the density is defined in g cm-3. The 
numbers following the density value define the construction of the cell based on the 
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combination of surfaces that are defined in the surface card later on in the input file. 
A negative number identifies the internal aspect of surfaces and a positive number 
the external aspect. For example, the outer tube is defined as cell number 3, 
consisting of material number 3, a density of 2.7 g cm-3 and is defined as the closed 
region inside surface number 3 and outside surface number 4. Cell 8 is an example 
where a union of surfaces is used to define a complex geometry. Cell number 2 
defines the limits of the modelled world. The modelled world identifies the total 
volume in which the geometry is confined. The modelled world is everything outside 
of the cells denoted by the hash symbol (#) and consists of air at atmospheric 
pressure. 
 
4.8.2 Surface card 
 
The second section of the MCNP5 input file contains all the surface information and 
is separated from the cell card by a blank line called a blank line delimiter. 
 
The geometry of the calibrator is simplified by its cylindrical design. This has allowed 
the use of in-built macro body functions in the input file. The macro body used for the 
construction is a right circular cylinder (RCC). A RCC is defined by the following 
parameters: 
 
RCC vx vy vz hx hy hz R 
 
where vx, vy and vz are the x, y and z Cartesian coordinates of the base of the 
cylinder, hx, hy and hz represent the height of the cylinder in the x, y and z directions 
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and R is the radius of the cylinder. It can be seen from the surface cards that the 
outer tube of the chamber can be defined as the space between the internal surface 
of cylinder 4 and the external surface of cylinder 3. 
 
 
 
The universe within which the model resides is a sphere of radius 25 cm. the 
specification of the sphere is: 
SO R 
 
where SO denotes a sphere centred at the origin and R is the radius of the sphere. 
Any particle reaching this surface of the sphere will be terminated at this point. The 
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radius is kept reasonably tight to the Fidelis model to negate particle histories that 
will not contribute to the tallies.  
 
The MCNP5 model of the P6 vial is designed to replicate that of a P6 vial as closely 
as possible within the constraints of the MCNP5 geometry capabilities. The P6 vial 
consists of a number of curved surfaces that are impractical to model in MCNP5. 
The vial is therefore constructed of three separate cylinders to represent the body, 
neck and the top of the vial. 
 
4.8.3 Mode card 
 
The final section of the MCNP5 input file contains the information to allow the 
MCNP5 programme to interpret the file. The mode card specifies the type of 
transport to be considered in the simulation. The mode card is specified as follows: 
 
 
 
In this specification, the MCNP5 programme is instructed to undertake some 
simplification of the physics modelling by considering photon transport only. The 
simplification requires that all ionising events from photon interactions are 
transmitted in the same direction as the photon and that electron energy deposition 
is immediate (X-5 Monte Carlo Team, 2003). 
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4.8.4 Material card 
 
The material card specifies the composition of each material.  
 
 
 
Each material is firstly defined by a number, in this instance m1 through to m10. 
These numbers are used in the second column of the cell cards to define the 
material for that particular cell. The next number indicates the atomic component in 
the format: 
ZZZAAA.nnX 
where ZZZ is the atomic number, AAA is the mass number, nn is the cross sectional 
identifier (default cross sectional library used if left blank) and X is the class of data 
(again, default used if left blank). Only the pure element form is considered in this 
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model and therefore the mass numbers are not adjusted. All other defaults are 
accepted. 
Next to the atomic definition is the fraction. The fraction can either be expressed as a 
nuclide fraction or, with a negative sign prefix, as a weight fraction. For example, 
material 7 is defined as water based solution. This could be expressed as   
m7 1000 -0.112 
 
8000 -0.888 
   
or 
m7 1000 0.667 
 
8000 0.333 
   
Both of these are acceptable nomenclatures.  
 
4.8.5 Importance card 
 
The first line beginning with imp:p details the importance of each of the cells. 
 
 
 
The importance function is a key element of the MCNP5 code in undertaking 
variance reduction and allowing statistically significant results for a smaller number 
of simulated particles. As the active region (nitrogen gas) fully surrounds the sample, 
variance reduction is less of an issue in gaining a statistically relevant result in this 
Page | 59 
 
geometry. In this example, all the cells have the sample importance value except the 
outside world, where a particle reaching this point will be terminated. 
 
4.8.6 Source definition card 
 
The source definition card defines the particulars of the source. 
 
 
 
 
In the above example an 123I source is simulated. The particle type is defined as 
par=2 which simulates photons. The energies and emission probabilities of the 
source are specified erg=d2 with reference to si2 and sp2. All energies are in MeV. 
The cell=10 card identified that the photons are to emanate from cell 10, the 
radionuclide solution in the P6 vial. When using the cell card to identify a cell for 
emissions of the photons, the extent of the photons and sampling emission 
distributions also have to be specified using the rad card. The rad=d1 identifies the 
distributions as per the si1 and sp1 cards. The distributions are set to be spherical 
with a radius of 2 cm and a uniform sampling within this region. Providing this 
distribution lies within cell 10, the photons will be simulated at a uniformly random 
location within the cell volume. 
Page | 60 
 
4.8.7 Tally card 
 
The tally card within the input file instructs the MCNP5 programme what information 
to return from the simulation. All simulations must include a tally card or a critical 
failure will be returned.  
 
 
 
The tally selected for this initial simulation is the f6 tally. The f6 tally provides a track 
length estimate of energy deposited in MeV normalised per starting particle. Cell 11, 
the nitrogen gas, is defined as the volume over which the tally is acquired. The 
ionisation current (I) generated in a radionuclide calibrator can be expressed as: 
 
W
NeEdI ...Equation 4.1 
 
where N is the number of photons emitted per second (assumed monoenergetic), e 
is the electron charge, W is the energy required to create an ion pair in the gas and 
Ed is the energy deposited in the gas per photon of emission (Gostely and 
Laedermann, 2000). The value of W is dependent on the gas used in the chamber 
but is typically between 20 and 45 eV (Prekeges, 2011, p.3). For a given sample 
activity, the ionisation current is dependent on the energy deposited in the gas and 
therefore the f6 tally is a suitable surrogate for ionisation current. 
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Each tally result also has an estimated relative error, defined as one standard 
deviation of the mean, divided by the mean. (X-5 Monte Carlo Team, 2003, p.1-6). 
The significance of the range of errors is given in Table 4.5. 
 
Range of estimated 
relative error 
Quality of the tally 
0.5 to 1.0 Not meaningful 
0.2 to 0.5 Factor of a few 
0.1 to 0.2 Questionable 
<0.10 Generally reliable 
<0.05 
Generally reliable for point 
detectors 
Table 4.5: Estimated relative errors and the suggested corresponding quality of the 
tally (X-5 Monte Carlo Team, 2003, p.1-7) 
 
An estimated relative error of 0.10 equates to an uncertainty in the tally of ±10% at 
one standard deviation of the mean (following the central limit theorem). At three 
standard deviations, the uncertainty is ±30%. Relative errors in excess of 0.10 can 
therefore cast doubt on the reliability of the tally result. For the remaining MCNP5 
simulations undertaken, a more stringent ±5% maximum uncertainty was employed 
to improve the tally precision. However, the relative error gives no indication of the 
accuracy of the result. which can be estimated by comparative measurements with 
the physical system (X-5 Monte Carlo Team, 2003, p.1-6). 
  
Page | 62 
 
4.8.8 Particle and print card 
 
The final three lines in the MCNP5 input file specify the number of particles to be 
simulated and the printing requirements of the returned tallies. 
 
 
 
In this instance, the number of particles simulated is 1×106. As discussed in Chapter 
2, the estimated relative error depends on the number of particle histories. The 
number of histories required to meet the minimum ±5% uncertainty constraint 
specified in 4.8.7 was determined by increasing the number of histories until the 
constraint was achieved. (Any instances where the constraint was not met are noted 
where applicable). The prdmp and print functions prompt the MCNP5 programme to 
return the tally results periodically and also as a final print out. 
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4.8.9 Geometry visualisation 
 
Distributed with MCNP5 is a visualisation tool called "vised" (version MCNP5-Nov-
2005-19L). The visual editor is useful in confirming that the geometries are accurate 
and as described in the input file. 
 
The first visualisation shown in Figure 4.3 is the outer tube, base and top of the 
calibrator. The chamber has been rotated to provide a 3D visualisation of the 
chamber for more detail. 
 
 
Figure 4.3: Base, top and outer tube of the Fidelis chamber 
 
The next visualisation (Figure 4.4) shows the inner tube and the surrounding 
electrode. The nitrogen gas is composed of the volume between inner and outer 
tube excluding the electrode. 
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Figure 4.4: Inner tube and electrode 
The P6 vial jig and the vial can be seen in Figure 4.5. An opening in the jig allows for 
the placement of the P6 vial.  
 
Figure 4.5: Visual depiction of the jig and the vial 
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2D representations of the geometry are shown in Figures 4.6 and 4.7. The first figure 
shows a cross section through the middle of the calibrator. The vial can be seen 
resting in the jig and located in the centre of the chamber. The second figure is an 
aerial cross section that shows the geometry as a series of right centred cylinders. 
 
 
Figure 4.6: Cross-sectional depiction through the sagittal aspect of the Fidelis 
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Figure 4.7: Cross-sectional depiction through the transverse aspect of the Fidelis 
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4.9 Validation of the Monte Carlo model 
 
An integral part of a calibrator response is the sensitivity of the calibrator to photons 
of varying incident energy. The sensitivity of the calibrator depends on a number of 
aspects including the calibrator design and material composition. Prior to modelling, 
the response of a calibrator would be assessed experimentally, using standard 
sources. In a similar method to the determination of calibration factors, with the 
additional knowledge of the abundance and emissions of the radionuclide, a 
sensitivity curve can be experimentally determined. Once the sensitivity curve for the 
calibrator has been characterised, it is possible to derive calibration factors for 
radionuclides providing the emission and energy characteristics are known. 
 
The advantage of applying a Monte Carlo approach is that monoenergetic photons 
can be simulated and therefore issues regarding the accurate characterisation of 
radionuclides used for the sensitivity curve determination are negated. However, 
these issues are still present when considering the derivation of calibration factors. 
 
The initial MCNP5 model of the Fidelis was concerned with the generation of a 
sensitivity curve to elucidate potential issues with the assay of 123I.  
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4.9.1 Monte Carlo Fidelis sensitivity curve  
 
To produce the sensitivity curve for the Monte Carlo Fidelis model, monoenergetic 
photons ranging from 10 keV up to 700 keV were simulated from an aqueous 
radionuclide solution within the P6 vial. Each simulation was run for 1×106 photons 
and the average energy deposited in the nitrogen gas per starting particle was 
recorded. The statistical precision of each tally was inspected to ensure that the 
estimated relative error was less than 0.05. 
 
The results of the simulation are shown in Table 4.6. 
 
Figure 4.8 shows the MCNP5 modelled sensitivity curve for the full energy range 
simulated as per Table 4.6. 
 
The region of particular interest for 123I within the sensitivity curve concerns 20 to 200 
keV. For clarity, this region is reproduced in Figure 4.9. 
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Photon Energy 
keV 
 
 
Energy deposited 
MeV 
 
 
Energy deposited 
keV 
 
 
Energy deposited 
eV 
 
 
  
 
 
 
2.5  0.00 
 
0.00 
 
0.00 
5.0  0.00 
 
0.00 
 
0.00 
7.5  0.00 
 
0.00 
 
0.00 
10.0  0.00 
 
0.00 
 
0.00 
12.5
a
  1.10×10
-8
 
 
0.00 
 
0.01 
15.0
a
  5.30×10
-7
 
 
0.00 
 
0.53 
17.5  4.75×10
-6
 
 
0.00 
 
4.75 
20.0  1.67×10
-5
 
 
0.02 
 
16.72 
22.5  3.50×10
-5
 
 
0.04 
 
35.03 
25.0  5.48×10
-5
 
 
0.05 
 
54.84 
27.5  7.19×10
-5
 
 
0.07 
 
71.93 
30.0  8.51×10
-5
 
 
0.09 
 
85.06 
32.5  9.43×10
-5
 
 
0.09 
 
94.30 
35.0  1.00×10
-4
 
 
0.10 
 
100.23 
40.0  1.06×10
-4
 
 
0.11 
 
105.71 
50.0  1.09×10
-4
 
 
0.11 
 
108.81 
60.0  1.14×10
-4
 
 
0.11 
 
114.22 
70.0  1.24×10
-4
 
 
0.12 
 
124.34 
80.0  1.38×10
-4
 
 
0.14 
 
138.35 
90.0  1.55×10
-4
 
 
0.15 
 
154.97 
100.0  1.74×10
-4
 
 
0.17 
 
173.63 
110.0  1.96×10
-4
 
 
0.20 
 
196.40 
125.0  2.26×10
-4
 
 
0.23 
 
225.54 
150.0  2.81×10
-4
 
 
0.28 
 
281.19 
175.0  3.39×10
-4
 
 
0.34 
 
338.96 
200.0  3.98×10
-4
 
 
0.40 
 
397.68 
250.0  5.15×10
-4
 
 
0.52 
 
515.15 
300.0  6.31×10
-4
 
 
0.63 
 
631.15 
350.0  7.45×10
-4
 
 
0.75 
 
745.45 
400.0  8.58×10
-4
 
 
0.86 
 
857.77 
450.0  9.67×10
-4
 
 
0.97 
 
966.68 
500.0  1.07×10
-3
 
 
1.07 
 
1074.21 
550.0  1.18×10
-3
 
 
1.18 
 
1178.07 
600.0  1.28×10
-3
 
 
1.28 
 
1280.19 
650.0  1.38×10
-3
 
 
1.38 
 
1380.13 
700.0  1.48×10
-3
 
 
1.48 
 
1476.98 
a relative error exceeded 0.05 
Table 4.6: Energy deposited per starting particle in the nitrogen gas 
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Figure 4.8: Monte Carlo sensitivity curve for the Fidelis model 
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Figure 4.9: Monte Carlo sensitivity curve for the Fidelis model in the region 7.5 – 200 
keV 
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4.9.2 Discussion of Monte Carlo Sensitivity curve 
 
In this particular configuration, the threshold simulation photon energy for energy 
deposition in the nitrogen gas is 12.5 keV.  In two instances the relative error (noted 
by a subscript a) exceeded 0.05. These related to the two low energy photon 
simulations at 12.5 keV and 15.0 keV. With particular reference to the emissions of 
123I, the low energy x-ray emissions around 27 to 31 keV are located on an 
increasing gradient in the sensitivity curve. The sensitivity of the 159 keV gamma 
radiation in this configuration is approximately 4 times higher than that of the x-rays. 
The sensitivity curve therefore implies that the predominant contribution to the 
ionisation current for 123I in the modelled configuration will be the principal gamma 
radiation.   
 
4.9.3 Validation of the sensitivity curve 
 
Validation of the measurements undertaken on the Fidelis is the ideal situation to 
allow for a comparison with the Monte Carlo model. Potentially, practical 
measurements could be made to validate the model for a known number of 
radionuclide solutions. However, this can be difficult because of the unknown activity 
impurities. Alternatively, using a Monte Carlo model, a number of radionuclides in a 
P6 vial can be simulated and compared with the Fidelis factors generated by NPL. 
The radionuclides used for assessment were: 109Cd, 241Am, 51Cr, 7Be, 57Co, 99mTc, 
67Ga, 139Ce, 123I, 113mIn, 203Pb, 75Se, 131I, 111In, 137Cs, 54Mn and 60Co. These 
radionuclides were chosen for the validation due to their predominant photon only 
emissions and the fact that the emissions have been characterised in the literature. 
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Table 4.7 details the principal emissions and emission probabilities of these 
radionuclides. 
Radionuclide 
Principal x-ray or gamma 
emissions 
(keV) 
Emission probability 
(%) 
109Cd 
88.03 
22.16 
21.99 
24.94 
25.46 
24.91 
29.84 
31.86 
3.61 
54.7 
29.0 
9.85 
2.76 
5.05 
4.63 
3.64 
241Am 
 
 
26.34 
33.19 
59.54 
13.93 
17.51 
20.98 
15.88 
11.89 
2.4 
0.119 
35.7 
22.4 
30.5 
7.31 
0.505 
1.23 
51Cr 
320.1 
4.952 
4.945 
5.427 
5.427 
9.83 
13.3 
6.7 
1.76 
0.888 
7Be 477.6 10.3 
57Co 
14.41 
122.1 
136.5 
692.0 
6.404 
6.391 
7.058 
7.058 
9.19 
85.6 
10.6 
0.16 
33.4 
16.9 
4.51 
2.29 
99mTc 
140.5 
18.37 
18.25 
20.62 
88.9 
4.03 
2.12 
0.688 
67Ga 
91.27 
93.31 
184.6 
209.0 
300.2 
393.5 
494.2 
794.4 
887.7 
8.639 
8.616 
3.07 
38.3 
20.9 
2.37 
16.8 
4.7 
0.068 
0.0513 
0.145 
32.8 
16.7 
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9.572 
9.572 
4.49 
2.30 
139Ce 
165.9 
34.42 
33.03 
37.8 
38.75 
37.72 
4.649 
5.123 
79.1 
42.4 
23.1 
8.27 
3.10 
4.28 
4.93 
5.20 
123I 
27.20 
27.47 
30.94 
31.00 
31.71 
159.00 
248.00 
281.0 
346.3 
440.0 
505.3 
529.0 
538.50 
624.60 
687.90 
735.80 
783.60 
24.6 
45.8 
44.6 
8.66 
2.66 
82.80 
0.071 
0.079 
0.125 
0.425 
0.314 
1.380 
0.379 
0.083 
0.027 
0.061 
0.059 
113mIn 
391.7 
24.21 
24 
27.28 
27.24 
64.2 
13.1 
6.99 
2.40 
1.24 
203Pb 
279.2 
401.3 
680.5 
72.87 
70.83 
82.57 
84.97 
82.11 
10.26 
12.23 
14.41 
80.1 
3.44 
0.697 
43.1 
25.5 
9.84 
4.27 
5.12 
15.8 
15.3 
2.83 
75Se 
66.05 
96.73 
121.1 
136.0 
198.6 
264.7 
279.5 
303.9 
400.6 
10.54 
10.51 
1.1 
3.5 
17.7 
60.6 
1.5 
59.4 
25.2 
1.31 
11.3 
31.8 
16.3 
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11.73 4.68 
131I 
80.18 
17.72 
284.3 
325.8 
364.5 
503.0 
637.0 
624.7 
722.9 
29.78 
29.46 
2.62 
0.265 
6.06 
0.251 
81.2 
0.361 
7.27 
0.22 
1.80 
2.59 
1.40 
111In 
171.3 
245.5 
23.17 
22.98 
26.09 
26.64 
26.06 
90.5 
94.0 
44.3 
23.6 
8.07 
2.35 
4.14 
137Cs 661.66 84.99 
54Mn 834.8 100 
60Co 
1173 
1332 
99.9 
100 
 
Table 4.7: Principal photon energies and emission probabilities for the radionuclides 
used to validate the Monte Carlo model 
 
The radionuclides detailed in Table 4.7 were simulated as solutions within the P6 
vials and the energy deposited in the nitrogen gas tallied. Each simulation was run 
for 1×106 photons and the average energy deposited in the nitrogen gas per starting 
particle was recorded. The statistical precision of each tally was inspected to ensure 
that the estimated relative error was less than 0.05. 
 
Table 4.8 details the results of the simulations. Columns 1, 2 and 3 detail the 
radionuclide used in the simulation, the published NPL calibration factor (P6 vial) and 
the published uncertainty in the calibration factor. The 4th column details the 
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fractional calibration factor as published by NPL for a P6 vial relative to 60Co. The 
energy deposited is then stated per MeV and keV respectively per starting photon for 
the Monte Carlo model. The energy deposited in the nitrogen gas must be 
normalised to the total emission probability per radioactive decay. For example, the 
principal photon for 51Cr has a 9.83% emission probability. As Monte Carlo code 
samples sequential photons, the total recorded energy deposition is approximately 
10 times higher than what would be seen for a sample of 51Cr in the Fidelis. 
Similarly, 60Co has an emission probability of 199.9% for both of the principal 
photons, the energy deposited in the model is therefore approximately half of what 
would occur with a radioactive sample.  
 
The fractional calibration factors for the Monte Carlo model and the published NPL 
values are graphically represented in Figure 4.10. 
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4.9.4 Discussion of the sensitivity curve validation 
 
The Monte Carlo model shows good concordance with the physical calibration 
factors derived by NPL over the energy ranges from 20 – 1200 keV. As there is a 
close relationship with the fractional calibration factors, estimations of the calibration 
factors based on the Monte Carlo simulations are possible. Two methods may be 
utilised to undertake a derivation of a new calibration factor. Firstly, for the 
configuration simulated, the sensitivity curves in Figures 4.8 and 4.9 may be used to 
calculate a calibration factor relative to 60Co. Secondly, Monte Carlo simulations may 
be undertaken for this model and new calibration factors derived based on the 
fractional energy deposition in the nitrogen gas. 
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Table 4.8: Results of the validation of the Monte Carlo Fidelis compared to the published NPL calibration factors 
Radionuclide 
Fidelis 
Calibration 
Factor 
(pA/MBq) 
Fidelis 
Uncertainty 
in factor 
(%) 
Fractional 
Fidelis 
calibration 
factor 
MCNP5 
Fidelis 
energy 
deposited 
(MeV) 
MCNP5 
Fidelis 
energy 
deposited 
(keV) 
Total 
emissions 
per 
starting 
particle 
MCNP5 
normalised 
to emissions 
per starting 
particle 
Fractional 
MCNP5 
calibration 
factor 
109Cd 0.1176 0.67 0.005 3.70E-05 0.04 1.132 0.042 0.009 
241Am 0.228 0.38 0.010 4.55E-05 0.05 1.002 0.046 0.009 
51Cr 0.3327 0.67 0.015 2.05E-04 0.20 0.325 0.067 0.014 
7Be 0.5182 1.17 0.023 1.03E-03 1.03 0.103 0.106 0.022 
57Co 1.174 0.67 0.053 1.33E-04 0.13 1.627 0.217 0.045 
99mTc 1.227 0.84 0.055 2.42E-04 0.24 0.957 0.232 0.048 
67Ga 1.547 1.34 0.070 2.12E-04 0.21 1.427 0.303 0.063 
139Ce 1.652 0.84 0.075 1.95E-04 0.19 1.704 0.332 0.069 
123I 1.685 0.84 0.076 2.02E-04 0.20 1.720 0.348 0.072 
113mIn 2.72 0.67 0.123 6.27E-04 0.63 0.879 0.551 0.114 
203Pb 3.134 0.67 0.141 3.34E-04 0.33 2.060 0.689 0.143 
75Se 3.923 1.67 0.177 3.34E-04 0.33 2.344 0.782 0.162 
131I 3.999 0.34 0.180 7.89E-04 0.79 1.040 0.821 0.170 
111In 4.088 0.67 0.184 3.03E-04 0.30 2.670 0.810 0.168 
137Cs 5.751 0.67 0.259 1.40E-03 1.40 0.850 1.192 0.247 
54Mn 8.148 0.34 0.368 1.73E-03 1.73 1.000 1.728 0.358 
60Co 22.17 0.38 1.000 2.41E-03 2.41 1.999 4.824 1.000 
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Figure 4.10: Graphical representation of the normalised calibration factors for the Fidelis compared to the Monte Carlo model 
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CHAPTER 5: MONTE CARLO SIMULATION OF FACTORS 
INFLUENCING THE PERFORMANCE OF A FIDELIS 
CALIBRATOR 
 
5.1 Introduction 
 
In the previous chapter a Monte Carlo model of a Fidelis radionuclide calibrator was 
produced and validated against NPL published calibration factors. 
 
As previously stated, syringe factors for the Fidelis calibrator do not appear in the 
published list of NPL approved calibration factors (NPL, 2015c). The knowledge of 
accurate syringe factors is important for all radionuclide calibrators and in particular 
the Fidelis secondary standard calibrator, where cross-calibrations of these factors 
may be undertaken against a field calibrator. 
 
In this chapter, a syringe calibration factor is derived for a commonly used syringe for 
intra venous administrations within the Medical Physics Department of the University 
Hospital of Wales, namely a 1 ml BD Plastipak™ syringe. 
 
Typically, most radionuclide calibrators use a jig to hold the syringe in a reproducible 
position. However, in this instance, there is no syringe jig supplied with the Fidelis. 
Substitute jigs are not considered here as the difference in calibration factor is 
assessed for the syringe composition as opposed to any jig composition that may 
provide absorption and scatter media. 
  
Page | 81 
 
5.2 Monte Carlo syringe model 
 
The Monte Carlo model of a 1 ml BD Plastipak™ syringe is shown in Figure 5.1. 
Similar to the Monte Carlo design of the P6 vial, the syringe consists of a number of 
cylindrical surfaces which, when combined together, form the tip of the syringe, the 
main outer shaft and the rubber tipped plunger. The syringe is predominately 
constructed of plastic with a wall thickness of 0.1 cm and a density of 1.19 g cm-3. 
The rubber tip at the end of the plunger has a density of 0.92 g cm-3. 
 
As per local protocol in the Medical Physics Department, assays of radioactivity in a 
syringe are undertaken with a blind hub. The blind hub is placed on the tip of the 
syringe to help ensure the contents remain sterile during the assay and transport of 
the radiopharmaceutical and also to prevent loss of liquid from the syringe. 
 
  
Figure 5.1: Monte Carlo model of a 1 ml BD Plastipak™ syringe 
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The syringe location within the well of the chamber can be seen in Figure 5.2. 
 
 
Figure 5.2: location of the syringe within the Fidelis model 
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5.3 Characterisation of volume effect for 123I in a 1 ml syringe 
 
The position of the syringe in the chamber is simulated to be similar to that of the P6 
vial described in chapter 4. However, the volume of the syringe is considerably lower 
than the 4 ml simulated in the P6 vial. Variations in syringe volume are known to 
have an effect on the amount of ionisation current produced (Gadd et al., 2006). 
Typically, volumes between 0.1 and 0.5 ml are dispensed by the radiopharmacy in 
the Medical Physics Department. It is therefore prudent to determine the variation in 
energy deposited in the chamber between these volumes. 
 
A syringe of construction detailed in section 5.2 was modelled in the Fidelis chamber 
with a series of simulations. Initially, the syringe contained a 0.1 ml solution of 123I 
and following each simulation, the volume solution was incremented to 0.5 ml in 0.1 
ml steps. Each simulation was run for 1×106 photons and the average energy 
deposited in the nitrogen gas per starting particle was recorded. The statistical 
precision of each tally was inspected to ensure that the estimated relative error was 
less than 0.05. 
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5.3.1 Volume effect results 
 
The energy deposited in the nitrogen gas for each syringe volume is shown in Table 
5.1. 
 
Syringe 
volume 
(ml) 
Energy deposited 
(MeV) 
Energy deposited 
(eV) 
Ratio to 
0.1 ml 
0.1 2.44×10-4 243.87 1.000 
0.2 2.43×10-4 243.10 0.997 
0.3 2.43×10-4 242.78 0.996 
0.4 2.43×10-4 242.58 0.995 
0.5 2.42×10-4 242.39 0.994 
Table 5.1: variation in energy deposition per syringe radionuclide solution volume of 
123I 
 
The variation in energy deposited per syringe volume can be seen in Figure 5.3. 
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Figure 5.3: Syringe volume variation for 1 ml BD Plastipak™ syringe 
 
5.3.2 Discussion of volume effect for 123I in a 1 ml syringe 
 
As can be seen from Table 5.1, there is less than 1% variation in the energy 
deposited per starting particle in the nitrogen gas between 0.1 ml and 0.5 ml. A least 
squares fit model was used in Excel™ to characterise the relationship between the 
energy deposited and the syringe volume and is given by: 
 
Energy deposited per starting particle (eV) = -0.909ln(volume (ml)) + 241.72 .... 
Equation 5.1 
 
This logarithmic relationship allows for a calibration factor derived for this syringe at 
a given volume to be transferred to the same syringe at a different volume. 
Page | 86 
 
5.3.3 Derivation of syringe calibration factors 
 
The variation in energy deposited by the 1 ml BD Plastipak™ syringe for different 
volumes can be compared with the P6 vial as shown in Table 5.2. The calibration 
factor for the P6 vial was validated in chapter 4 for the Monte Carlo model for 123I. 
Instead of being considered in terms of pA/MBq, for modelling purposes the 
calibration factor can be considered in terms of energy deposited per starting 
particle. As the energy deposited is normalised per starting particle, the energy 
deposited in the syringe simulations can be compared to the P6 vial. The ratio of the 
energy deposited in the nitrogen gas for the syringe and vial can be used to 
determine the percentage difference and to derive a new calibration factor for the 
syringe. 
 
Container 
Volume 
(ml) 
Energy 
deposited 
(MeV) 
Fidelis 
published 
calibration 
factor 
(pA/MBq) 
Fidelis derived 
calibration 
factor 
(pA/MBq) 
% 
difference 
to vial 
P6 vial 4.0 2.02×10-04 1.685 1.685 0.0 
BD Plastipak™ 
1ml syringe 
0.1 2.44×10-04 - 2.034 20.7 
BD Plastipak™ 
1ml syringe 
0.2 2.43×10-04 - 2.0027 20.3 
BD Plastipak™ 
1ml syringe 
0.3 2.43×10-04 - 2.024 20.1 
BD Plastipak™ 
1ml syringe 
0.4 2.43×10-04 - 2.023 20.0 
BD Plastipak™ 
1ml syringe 
0.5 2.42×10-04 - 2.021 20.0 
Table 5.2: Percentage difference between the vial and the syringe simulations with 
derived syringe calibration factors 
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5.3.4 Discussion of syringe calibration factors 
 
For this particular example of a 1 ml BD Plastipak™ syringe, we can see from Table 
5.2 that there is up to 21% increase in the energy deposited in the nitrogen gas when 
the 123I is in a syringe as compared to a P6 vial. These figures are in keeping with 
those reported by Tyler and Woods (2003). The authors reported that the range of 
syringe factors for a number of syringes containing 123I was between 1.71 – 1.90 
pA/MBq. The maximum calculated calibration factor of 2.034 pA/MBq is somewhat 
above the authors quoted range, but the paper does not specify the particulars of the 
syringes that they used for assay. However, it must be borne in mind that these 
calibration figures do not appear in the published NPL calibration factors document 
(NPL, 2015c). 
 
Although the variation in calibration factors for only one syringe is presented for 
analysis here, it is evident that the percentage differences observed in the model, 
while consistent for this type of calibrator, are somewhat reduced to those quoted for 
other chambers in the literature. As previously explained, the design of the chambers 
varies little and it is mainly the composition of the chamber materials and gas that 
change between models. The literature predominately presents chambers with argon 
as a chamber gas. An analysis of the Fidelis sensitivity curve with argon gas is 
therefore presented for comparison with nitrogen. 
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5.4 Fidelis chamber sensitivity curve with argon gas 
 
The sensitivity curve for an argon filled chamber has been experimentally 
determined and presented in the literature previously (Suzuki et al., 1976). Figure 5.4 
shows the sensitivity curve for a Capintec calibrator filled with argon.  
 
 
Figure 5.4: Sensitivity curve for a Capintec argon filled calibrator (reproduced from 
(Suzuki et al., 1976)). 
 
The Monte Carlo model used in Chapter 4 was adjusted to change the chamber gas 
from nitrogen to argon. Argon has an atomic number of 18 as compared to 7 for 
nitrogen. The pressure of the argon gas was kept consistent with the nitrogen gas at 
1 MPa.  
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The individual gas constant for argon is 208.1 J kg-1 K-1 and the density of the gas 
was calculated to be 0.01634 g cm-3. 
 
The results of the simulations can be seen in table 5.3 and are graphically displayed 
in Figure 5.5. 
Photon Energy 
keV 
Energy deposited 
MeV 
Energy deposited 
keV 
Energy deposited 
eV 
10 0 0.0 0.0 
20 3.69×10-04 0.3694 369.4 
25 1.39×10-03 1.3899 1389.9 
30 2.31×10-03 2.3058 2305.8 
35 2.75×10-03 2.7495 2749.5 
40 2.81×10-03 2.8097 2809.7 
45 2.68×10-03 2.6774 2677.4 
50 2.46×10-03 2.4600 2460.0 
55 2.23×10-03 2.2298 2229.8 
60 2.02×10-03 2.0168 2016.8 
65 1.82×10-03 1.8216 1821.6 
70 1.65×10-03 1.6509 1650.9 
75 1.50×10-03 1.5031 1503.1 
80 1.38×10-03 1.3788 1378.8 
85 1.27×10-03 1.2710 1271.0 
90 1.18×10-03 1.1802 1180.2 
95 1.10×10-03 1.1027 1102.7 
100 1.04×10-03 1.0366 1036.6 
125 8.34×10-04 0.8335 833.5 
150 7.51×10-04 0.7505 750.5 
175 7.30×10-04 0.7296 729.6 
200 7.42×10-04 0.7418 741.8 
225 7.73×10-04 0.7731 773.1 
250 8.18×10-04 0.8181 818.1 
275 8.69×10-04 0.8694 869.4 
300 9.26×10-04 0.9258 925.8 
400 1.18×10-03 1.1751 1175.1 
500 1.43×10-03 1.4329 1432.9 
600 1.69×10-03 1.6862 1686.2 
700 1.93×10-03 1.9319 1931.9 
Table 5.3: Energy deposited per starting particle in the argon gas 
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Figure 5.5: Monte Carlo sensitivity curve for the Fidelis with argon gas 
 
5.4.1 Discussion Fidelis chamber sensitivity curve with argon gas 
 
The sensitivity curve for the Fidelis chamber with argon gas shows a marked 
difference from the nitrogen sensitivity curve as shown in Figure 4.8. The argon 
sensitivity curve closely resembles the shape of the Capintec curve published by 
Suzuki et al. (1976). A peak in the sensitivity curve is seen at approximately 45 keV, 
with significant variation in sensitivity between 10 and 45 keV, the range in which the 
characteristic x-ray emissions of 123I occur. The main gamma emission of 123I (159 
keV) appears close to a local minimum within the sensitivity curve. For nitrogen the 
principal 123I gamma emission was approximately four times as great as that of the 
characteristic x-rays (from the sensitivity curve). For argon, we see that the relative 
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sensitivity has switched in favour of the characteristic x-rays, ranging from unity to 
three times more sensitive for x-rays in the region of 27 – 31 keV. 
 
5.4.2 Derivation of syringe calibration factors for fidelis filled with argon 
 
To investigate further the use of argon as the chamber gas in the Fidelis, the 
experiments simulated in sections 5.3.1 and 5.3.3 were repeated. 
 
The variation in energy deposited per syringe volume can be seen in Table 5.4 and 
graphically displayed in Figure 5.6. 
 
Syringe 
volume 
Energy deposited 
(MeV) 
Energy deposited 
(eV) 
Variation 
0.1 2.32×10-03 2323.44 1.000 
0.2 2.31×10-03 2309.26 0.994 
0.3 2.31×10-03 2305.57 0.992 
0.4 2.30×10-03 2302.99 0.991 
0.5 2.30×10-03 2301.24 0.990 
Table 5.4: syringe volume variation with argon gas 
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Figure 5.6: Syringe volume variation for 1 ml BD Plastipak™ syringe with a Fidelis argon 
filled chamber 
 
The variation in energy deposited by the 1 ml BD Plastipak™ syringe for different 
volumes can be compared with the P6 vial as shown in Table 5.5. There are no 
published calibration factors for the Fidelis with argon chamber gas. An estimation of 
the Fidelis chamber factor was undertaken as follows. The ratio of the energy 
deposited in the gas for a P6 vial was taken for the argon gas compared to the 
nitrogen gas and multiplied by the P6 calibration factor for nitrogen. This results in a 
calibration factor of 11.48 pA/MBq for a P6 vial in an argon filled Fidelis as opposed 
to 1.685 pA/MBq for nitrogen filled Fidelis. 
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Container 
Volume 
(ml) 
Energy 
deposited 
(MeV) 
Fidelis derived 
calibration 
factor 
(pA/MBq) 
% 
difference 
to vial 
P6 vial 4.0 1.38×10
-03 11.48 0.0 
BD Plastipak™ 
1ml syringe 
0.1 2.32×10
-03 16.05 68.8 
BD Plastipak™ 
1ml syringe 
0.2 2.31×10
-03 16.01 67.8 
BD Plastipak™ 
1ml syringe 
0.3 2.31×10
-03 16.00 67.5 
BD Plastipak™ 
1ml syringe 
0.4 2.30×10
-03 16.00 67.3 
BD Plastipak™ 
1ml syringe 
0.5 2.30×10
-03 16.00 67.2 
Table 5.5: Percentage difference between the vial and the syringe simulations for 
argon gas 
 
5.4.3 Discussion of derived of syringe calibration factors for the fidelis 
filled with argon 
 
The results validate some of the previous work that shows a range of 60 – 80 % 
difference in the reading between a vial and a syringe in an argon filled chamber. 
This is an interesting observation as it means that nitrogen filled chambers are more 
advantageous than argon filled chambers in ensuring a smaller variation when 
assaying 123I. The variation in calibrator response between a P6 vial and a 1 ml 
syringe for a nitrogen filled chamber was found to be up to 21%. The reason for the 
reduced variation can be deduced from Figures 4.8 and 4.9. The sensitivity of the 
chamber to the low energy x-ray emissions of 123I is four times less than the principal 
gamma peak. Hence the contribution of the x-rays to the response of the chamber is 
lower than that observed for argon gas.  One of the reasons why argon remains 
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more prevalent within radionuclide calibrators can be seen with the sensitivity curve 
for argon and the derived argon calibration factors. The energy deposited in the 
chamber is of the order of ten times higher for argon as opposed to nitrogen. This is 
advantageous in terms of optimising the amount of ionisation current produced per 
unit activity which, in turn, may lead to an increase in accuracy of ionisation current 
measurement. 
 
5.5 Use of a copper filter in the Fidelis 
 
As has been previously demonstrated, the degree of correction for a syringe in a 
Fidelis nitrogen filled chamber is somewhat lower than that for an argon filled 
chamber. The most commonly applied approach for correcting this discrepancy is 
the use of a copper filter. The following simulations were undertaken to determine 
the optimum thickness of copper to negate the discrepancy for nitrogen and argon 
filled Fidelis chambers. In both cases the copper filter was simulated in the Fidelis 
chamber. The vial jig was removed for the simulations with the copper filter. The 
geometry for the syringe can be seen in Figure 5.7. The length of the copper filter 
was such that it extended beyond the length of the calibrator. 
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Figure 5.7: Fidelis calibrator with syringe and copper filter 
 
The simulations were undertaken from 0.05 mm to 1.0 mm of copper and compared 
with the result without copper. The results are tabulated in Table 5.6. A graphical 
representation of the ratio of the copper filter measurements for nitrogen and argon 
can be seen in Figure 5.8. 
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Nitrogen Argon 
Cu filter 
thickness 
(mm) 
Syringe 
Energy 
deposited 
(MeV) 
Vial 
Energy 
deposited 
(MeV) 
Ratio 
Syringe 
Energy 
deposited 
(MeV) 
Vial Energy 
deposited 
(MeV) 
Ratio 
0 2.44×10-4 2.02×10-4 1.207 2.32×10-3 1.38×10-3 1.688 
0.05 2.05×10-4 1.85×10-4 1.109 1.33×10-3 8.93×10-4 1.487 
0.1 1.86×10-4 1.74×10-4 1.070 8.55×10-4 6.36×10-4 1.344 
0.2 1.71×10-4 1.65×10-4 1.038 4.98×10-4 4.40×10-4 1.133 
0.3 1.66×10-4 1.61×10-4 1.029 4.00×10-4 3.84×10-4 1.041 
0.4 1.63×10-4 1.58×10-4 1.027 3.68×10-4 3.65×10-4 1.010 
0.5 1.60×10-4 1.56×10-4 1.028 3.55×10-4 3.55×10-4 1.001 
0.6 1.58×10-4 1.54×10-4 1.029 3.49×10-4 3.49×10-4 0.999 
0.7 1.56×10-4 1.51×10-4 1.029 3.43×10-4 3.44×10-4 0.999 
0.8 1.54×10-4 1.49×10-4 1.030 3.38×10-4 3.39×10-4 1.000 
0.9 1.51×10-4 1.47×10-4 1.031 3.34×10-4 3.33×10-4 1.002 
1 1.49×10-4 1.45×10-4 1.032 3.30×10-4 3.28×10-4 1.004 
Table 5.6: Syringe and vial energy deposition in nitrogen or argon with varying 
thicknesses of copper 
Page | 97 
 
 
Figure 5.8: Copper filter ratios for nitrogen and argon 
 
5.5.1 Discussion of the use of a copper filter in the Fidelis 
 
From Table 5.6 and Figure 5.8 we can again see the variation in energy deposited 
between a syringe and a vial copper filtration.  The optimal copper filtration thickness 
for the nitrogen filled Fidelis is 0.3 mm, where the ratio of the syringe and vial 
readings stabilises to 3% of each other. For the argon filled Fidelis, stability is not 
achieved until 0.5 mm of copper filtration. However, the ratios of the syringe and vial 
measurements are unity, meaning that a copper filter is an excellent choice for a 
argon filled calibrator. The copper filter Fidelis calibration factors can be calculated 
by comparing the ratio of energy deposited in the gas with and without the optimal 
thickness of copper filtration. This can then be related to either the NPL published 
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factor for a P6 vial or the factor derived for the Fidelis with nitrogen. For nitrogen with 
a 0.3 mm thick copper filter, the 123I copper filter calibration factor is 1.34 pA/MBq 
and for argon, the factor is 2.96 pA/MBq with 0.5 mm copper filtration. 
 
5.6 Copper filter field radionuclide calibrator determination 
 
For subsequent syringe measurements, it is necessary to cross-calibrate a field 
radionuclide calibrator for 123I. The Medical Physics Department has three Capintec-
CRC15R radionuclide calibrators for the routine assay of radiopharmaceuticals. 
 
A 4 ml solution of 123I was dispensed into a Schott vial with the weight of the vial 
measured before and after filling to determine the mass of the solution. The activity 
of the Schott vial was then ascertained on the Fidelis calibrator using the appropriate 
calibrator factor. 
 
The activity of the Schott vial was measured using the three Capintec Calibrators 
with a 0.6 mm copper filter and compared to the Fidelis measurement. The Capintec 
calibration factor was adjusted when using the copper filter to show the same decay 
corrected reading as the Fidelis. 
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5.6.1 Results 
 
The activity of the 123I in the Schott vial was 140.4 MBq as assayed in the Fidelis. A 
Capintec calibration factor of #54 was derived based on the best concordance with 
the decay corrected Fidelis measurement. This copper filter calibration factor was 
implemented into routine practice and used for subsequent measurements in chapter 
7. 
 
5.7 Summary 
 
In this chapter a number of investigations were undertaken to determine the 
uncertainty in measuring 123I in a vial as compared to a syringe using the Fidelis. The 
results showed that for nitrogen filled chambers, up to 21% variation in measurement 
was seen. Based on the Monte Carlo simulations, a method for determining syringe 
calibration factors was devised and a number of Fidelis calibration factors for a BD 
Plastipak™ 1ml syringe were derived. 
 
The majority of commercially available calibrators employ argon as a chamber gas 
as opposed to nitrogen. The benefit of using argon is that its higher atomic number 
means the cross-section for the photoelectric effect is significantly higher. This result 
was evident when a sensitivity curve was generated for the Fidelis using argon as 
the chamber gas. The sensitivity curve derived for the argon filled chamber was 
similar to that previously seen in the literature (Suzuki et al., 1976). When comparing 
the 123I vial and syringe measurements, up to 69% variation was observed. Again, 
this is in keeping with previously reported variations in the literature. 
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Finally, copper filter simulations were undertaken for the syringe and vial for both 
nitrogen and argon filled Fidelis chambers. Copper was shown to be an effective 
attenuating material for the low energy x-ray emissions of 123I. For a nitrogen filled 
Fidelis chamber, 0.3 mm copper was sufficient to reduce the variation in the vial and 
syringe measurement to 3%. For argon, approximately double the copper filter 
thickness was required to reach unity in the ratio. 
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CHAPTER 6: RADIOIODINE THYROID UPTAKE AND 
ASSOCIATED UNCERTAINTIES 
 
6.1 Introduction 
 
In the previous two chapters, the potential uncertainties of the assay of 123I were 
detailed. In this chapter, the application of radioiodine in nuclear medicine is 
presented. The anatomy and physiology of the thyroid gland is described as the 
predominant target tissue following radioiodine administration. The thyroid uptake 
assessment as a means to differentiate between different thyroid diseases is 
detailed along with a discussion of some of the inherent uncertainties in the 
assessment. Finally, the aim of this section of work is presented. 
 
6.2 The thyroid gland 
 
The thyroid gland is a member of the endocrine system of glands. Along with the 
nervous system, one of the roles of the endocrine system is to maintain a stable 
internal environment within the body. To achieve this, glands secrete hormones into 
the blood stream and these target specific cells. The effects of the hormone are 
manifested in all parts of the body that have recepter cells specific to that hormone. 
The thyroid gland is located in the neck and consists of two lateral lobes (right 
thyroid gland and left thyroid gland) and a narrow connecting isthmus (Figure 6.1). 
The thyroid is anterolateral to the trachea and located below the larynx (Patton and 
Thibodeau, 2013). 
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Figure 6.1: Schematic of the thyroid gland (MedicalTerms.info, 2012) 
 
The tissues within the thyroid gland contain small spherical follicular cells which 
absorb I- from the blood. Once within the follicles, I- is converted to iodine before 
being synthesised and stored as a precursor to the excreted thyroid hormones. 
Iodine is therefore an important part of an individual‟s dietary intake and it is 
essential to ensure sufficient blood concentrations are available for absorption into 
the thyroid gland (and the subsequent production and release of thyroid hormones). 
 
The two main excreted hormones are T3 and T4, with the latter commonly known as 
thyroxine. The thyroid gland is stimulated to release thyroid hormones due to the 
influence of TSH, which is released from the pituitary gland. The release of T3 and T4 
into the blood results in an increase in the metabolic rate of cells. Through negative 
feedback, the levels of T3 and T4 are maintained within the blood to ensure normal 
rates of cell metabolism. 
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6.3 Diseases of the thyroid 
 
A number of diseases (both malignant and benign) have been identified that are 
related to the function of the thyroid. Of particular interest to nuclear medicine 
applications include thyroid cancers, hyperthyroidism and hypothyroidism. This study 
concentrates only on the diagnostic nuclear medicine assessment of hyperthyroidism 
and hypothyroidism. 
 
Hyperthyroidism (clinically known as thyrotoxicosis) is defined as the syndrome 
resulting from an excessive amount of circulating thyroid hormones. As the thyroid 
hormones are present throughout the body, an excess of hormones will affect a 
number of functional systems including the cardiovascular, respiratory and 
gastrointestinal systems. Clinical signs and symptoms of hyperthyroidism include 
increased heart rate, behavioural changes, anxiety and decrease in weight due to 
the increased cellular metabolic rate (Lazarus, 1994). A number of different 
etiologies can cause hyperthyroidism, with the most prevalent being Graves' disease 
(Vanderpump, 2011). The three main treatments for Graves' disease are anti-thyroid 
medications, sub-total thyroidectomy and radioiodine (Wheetman, 1994). 
 
Hypothyroidism is a term collectively used to describe a number of diseases that 
result in a reduction in thyroid hormones or, more rarely, a moderation of their effect 
on tissues (Amino and Tachi, 1994). Common symptoms of hypothyroidism include 
tiredness, lack of concentration, cold intolerance and unexplained weight gain 
(Ladenson, 2003). Similar to hyperthyroidism, a number of different etiologies can 
cause the condition including dietary iodine insufficiency. The most common cause 
of hypothyroidism in iodine-replete individuals is conditions of an autoimmune 
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nature, including Hashimoto‟s thyroiditis (Amino and Tachi, 1994). Hypothyroidism 
can usually be effectively treated with medications designed to synthetically replace 
the depleted thyroid hormones blood levels. 
 
6.4 Nuclear medicine thyroid uptake assessment 
 
Clinical diagnosis of hypo- or hyperthyroidism is usually based on a detailed patient 
history and biochemical testing. Although generally sufficient to make a diagnosis of 
hypo- or hyperthyroidism, the exact etiology of the underlying disease may not be 
apparent from such assessments. This is especially important to ascertain as the 
choice of therapy is dictated by the cause of the condition. 
 
The assessment of radioiodine thyroid uptake has become a widespread diagnostic 
nuclear medicine tool for assisting in the differentiation of hypothyroidism, or more 
usually, hyperthyroidism etiologies. The thyroid uptake is expressed as the 
percentage of administered radioiodine in the thyroid at a given time post 
administration. For hyperthyroidism, disorders can be separated into those that result 
in a high radioiodine uptake and those with a low radioiodine uptake. High 
radioiodine uptake treatments include medications, radioiodine therapy and surgery. 
Low radioiodine uptake is also associated with inflammatory thyroid conditions 
(subacute thyroiditis) or an extrathyroidal source of thyroid hormones. In this case, 
radioiodine is not an appropriate therapy as uptake of the tracer in the thyroid is very 
low and would provide little therapeutic benefit. Medications are often employed and 
found to be effective in offering symptomatic relief (such as beta-adrenergic blocking 
agents) for the majority of patients (Ross, 2003). 
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The thyroid uptake counter is one of two pieces of equipment used to assess the 
uptake of radioiodine within the thyroid. The other commonly used piece of 
equipment is a gamma camera, where the assessment of radioiodine uptake is 
undertaken in conjunction with imaging the radiopharmaceutical distribution in the 
thyroid gland. The measurement technique consists of the administration of 
radioiodine and following a suitable uptake period, typically of the order of 2 to 6 
hours, the accumulation of the radioiodine in the thyroid is assessed by the relative 
thyroid external radiation measurement compared to a standard activity within an 
appropriate tissue equivalent phantom. 
 
The two main radionuclides used for the assessment of thyroid uptake are 131I and 
123I, which are usually administered orally in the form of sodium iodide solution. The 
radioiodine is absorbed by the thyroid gland and is effectively trapped for the 
duration of the investigation. Biologically, both isotopes are treated identically in the 
body. Historically, 131I was commonly used for thyroid uptake assessments as it was 
the more widely available radioiodine. With the widespread availability of 123I in the 
1980s, 123I uptake assessments were found to be an effective surrogate for 131I with 
the added advantage of reduced patient radiation dose and completion of the 
assessment on the same day as administration (Floyd et al., 1985). 
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Like other nuclear medicine diagnostic procedures, standardisation of data 
acquisition is essential for reproducible thyroid uptake assessments and 
interpretation. Standardisation of the thyroid uptake measurement technique using 
131I was first proposed by the IAEA to ensure a consistent approach in the 
assessment (IAEA, 1962). More recent guidelines for undertaking the thyroid uptake 
assessment have been developed by the BNMS (BNMS, 2003) and the SNM (Balon 
et al., 2006). The SNM guidelines also quote a normal 123I thyroid uptake reference 
range of between 6% and 18% (for a 4 hour uptake), although, the guidelines 
caution that reference ranges may be influenced by other factors including the 
available equipment and patient population. 
 
6.5 Review of the uncertainties associated with thyroid uptake assessments 
 
The need for a consistent measurement technique has been well documented to 
ensure the validity and reproducibility of thyroid uptake assessments. The 
measurement usually consists of an assessment of the radioactivity in the neck as 
compared to a similar assessment of the radioactivity in a surrogate neck phantom. 
The measurements are usually conducted over a short period of each other and 
therefore the need to decay correct between each measurement is negated. An 
alternative approach, as adopted by the Medical Physics Department at the 
University Hospital of Wales, is to undertake two neck phantom measurements, as 
soon as possible prior to and then proceeding the neck assessment. The average of 
these measurements is therefore seen as an approximate mean value of the neck 
phantom measurements at the time of the patient measurements. It is important to 
note that the thyroid uptake assessment is not an absolute assessment of the 
radioiodine uptake in the thyroid, but a relative assessment as compared to a 
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suitable standard, as in this case, an equivalent or scaled activity of the radionuclide 
administered to the patient in a neck phantom. As previously noted, the need to 
determine normal ranges locally for the equipment and measurement arrangements 
is acknowledged by the SNM and published normal ranges should be used with 
caution (Balon et al., 2006). The SNM procedural guidelines identify the following as 
potential sources of error (Balon et al., 2006): 
 
 Variations in neck to detector distance 
 Inappropriate neck phantom 
 Improper centring of the probe over the patient's neck 
 Electronic instability 
 Background variation 
 Interfering food or medications 
 Contamination of the neck phantom 
 Recent administration of other radionuclides 
 
Each source of uncertainty is further explored along with an analysis of the potential 
detriment to the accuracy of the thyroid uptake assessment. 
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6.5.1 Variations in neck to detector distance 
 
Variations in neck to detector distance will originate from either poorly reproduced 
setup between the neck phantom and patient measurements or variations in thyroid 
depth within the patients neck. Typical measurement distances between the neck 
and the surface of the detector are in the range 25 and 30 cm (Balon et al., 2006). 
Any change in distance from the surface of the neck to the face of the detector will 
affect the measurement due to the inverse square law, resulting in an increase or 
decrease in the flux of photons hitting the face of the detector. Due to the nature of 
the inverse square law, small variations in distance can propagate as significant 
differences in flux at the face of the detector. For example, a change of 1 cm from 29 
cm to 30 cm would result in a difference of 6.6% in the measured flux at the surface 
of the detector. Some method is therefore required to ensure that the neck to 
detector or phantom to detector distance remains consistent between 
measurements. Within the Medical Physics Department at the University Hospital of 
Wales, a 10 cm spacer is located at the end of the detector collimator to assist in the 
vertical positioning of the detector above the patients neck. 
 
The effect of variations in thyroid depth in the neck on the thyroid uptake assessment 
will be two fold. Firstly, the distance will increase between the thyroid and the 
detector. As discussed in the previous paragraph, any changes in thyroid to detector 
distance will have a deleterious effect due to the inverse square law. Secondly, the 
amount of soft tissue between the thyroid and the face of the detector will also 
increase (in the case of increased thyroid depth). The result will be an increase in 
soft tissue attenuation via photoelectric absorption and Compton scattering. Any 
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increase in attenuation will ultimately affect the number of photons emanating from 
the thyroid that are measured within the counting window and incorporated into the 
thyroid uptake assessment. 
 
Variation in the size of the thyroid, the depth of the thyroid in the neck and separation 
of the thyroid lobes has been previously investigated. In a phantom study by 
O'Connor and Malone (1978), a strong dependence on the activity measured using a 
thyroid uptake counter was found with respect to thyroid depth for 131I, 99mTc and 125I. 
A much weaker dependence on variations in thyroid size and lobe separation was 
determined. The authors also noted the range of typical thyroid depths and standard 
deviation in the population and indicated that there were significant variations.  
 
The estimation of a correction factor for thyroid depth following 123I administration 
has been proposed previously by Martin and Rollo (1977). The method involved 
taking the ratio of the measured counts in the x-ray peak and those measured in the 
main gamma peak. The authors were able to produce a calibration curve to correct 
for thyroid depth. In a sample of 40 patients, the authors estimated a mean thyroid 
depth of 2.74 cm with the majority of thyroids at a greater depth than 1.5 cm, 
corresponding to the depth of the surrogate thyroid in the thyroid phantom. This 
discrepancy, once corrected, resulted in a increase of 23% in the uptake 
measurements on average and in the extreme up to +130% (Martin and Rollo, 
1977). However, the depth correction was based on a neck and thyroid gland 
phantom in which the depth of the thyroid was simulated with test tubes containing 
123I. Applying this approach to a clinical situation is uncertain as the depth of the 
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thyroid in the neck is not likely to be uniform in all directions and specific to a 
particular patient. 
 
More recently, a phantom study has been undertaken to assess the uncertainties in 
the determination of 131I activity with varying thyroid positions in the neck (Ośko et 
al., 2007). A correction factor for thyroid depth was devised based on the ratio of 
counts in the principal gamma peak of 131I compared to a region in the Compton 
scattering band. When applying the calibration to a group of 95 patients, thyroid 
depths in excess of the standard 20 mm depth were noted. A variation in 131I activity 
up to 30% due to thyroid depth was seen for the majority of patients.  
 
6.5.2 Inappropriate neck phantom 
 
As previously mentioned, quantitative radioiodine uptake in the thyroid is not the 
primary function of a standard thyroid uptake assessment. The assessment is based 
on a comparison against a standard neck phantom and therefore the dimensions 
and composition of the phantom are going to determine the value of the calculated 
thyroid uptake assessment. The IAEA guidance recommends a PMMA neck 
phantom for assessment of radioiodine thyroid uptake (IAEA, 1962). Vahjen et al. 
(1992) demonstrated significant differences in the assessment of thyroid uptake 
when using a water phantom as opposed to the recommended PMMA phantom. This 
was due to the differing attenuation properties and dimensions of the different 
phantoms. In some cases, they noted for patients with high radioiodine uptake, 
estimation of the thyroid uptake was in excess of 100% when using the water 
phantom. A PMMA type phantom as suggested by the IAEA was deemed to be more 
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appropriate (Vahjen et al., 1992). Vahjen et al. (1992) also noted the importance of 
considering the differences in phantoms when comparing thyroid uptake 
measurements between different centres. Chervu et al. (1982) also demonstrated 
significant errors, up to 23%, were seen when using three different "IAEA neck 
phantoms" with slight differences in 123I source positioning. 
 
As an alternative to using a neck phantom, the use of dual energy 123I imaging has 
been reported by Shapiro et al. (2014) for assessing thyroid uptake. In this case 
imaging of the thyroid was undertaken on a gamma camera using the 159 keV 
principal gamma emission photopeak window and a 130 keV scatter window. The 
ratio of thyroid counts in the two respective images was used to compensate for the 
loss of counts due to absorption in the neck. A high degree of concordance was 
noted between the results of the proposed method and uptake as assessed via 24 
hour urine sampling. This method indicates another application of dual counting in 
the iodine spectrum as detailed in the previous section. 
 
6.5.3 Improper centring of the uptake counter over the patient's neck 
 
Improper centring of the uptake counter over the patient's neck is acknowledged to 
be a source of error but is noted as not having been examined in the literature to any 
great extent. Improper centring of the uptake counter is due to lateral error in 
positioning above the thyroid gland. Positioning is usually undertaken without any 
adjunct imaging and is mainly based on the operator‟s expectation of the likely 
position of the thyroid gland. Another source of positioning error that can be 
introduced is via a slight tilt in the detector away from the normal to the thyroid. Any 
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tilt will result in the face of the detector not presenting at 90° to the thyroid gland. The 
result would be a reduction in the assessment of thyroid uptake, as the angle of 
acceptance of gamma rays emitting from the thyroid will effectively be reduced. 
 
6.5.4 Electronic instability 
 
Any electronic instability in the thyroid uptake counter equipment will have a negative 
effect on the thyroid uptake assessment. An assessment to simulate the effect of 
electronic instability was undertaken by Chervu et al. (1982) by varying the high 
voltage applied to the PMT and determining the variation of the detected counts as 
measured by a single channel analyser. The results showed that significant errors 
can be introduced if the high voltage is unstable and the time between the neck and 
thyroid measurements is protracted. 
 
It has also been demonstrated that dead time issues result in significant uncertainty 
in the thyroid uptake assessment. Maguire (1998) assessed the dead time losses for 
3.7 MBq 123I in a thyroid phantom measured on three different thyroid uptake counter 
systems. Two systems showed a percentage error between the measured and 
expected count rate of 1.2% and 4.4% respectively. The remaining system showed a 
much larger error of 25.2%. Lee et al. (1995) also demonstrated 10% count losses 
for a thyroid uptake counter for 1.85 MBq 123I in a thyroid phantom  
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6.5.5 Background variation 
 
Background variations can be an issue and is determined by the ambient 
background in the vicinity of the uptake counter and via a contribution from extra 
thyroidal accumulation of the radiopharmaceutical. 
 
Ambient background count rates in the vicinity of the uptake counter will depend on 
the location of the counter with respect to natural and artificial sources of radiation. 
Short term variability may be somewhat unavoidable, for example due to other 
patients in the vicinity who have been administered radiopharmaceuticals. The 
current practice in the Medical Physics Department at the University Hospital of 
Wales is to undertake a background count rate check prior to use [in this regard one 
is also assessing if the thyroid uptake counter is contaminated]. When using a 
spectral display, any discrepancies between the expected background spectrum 
displayed and that observed should warrant further inspection. 
 
The contribution of extra thyroidal radiopharmaceutical accumulation may influence 
the thyroid uptake assessment. The use of a collimator on the uptake counter is 
designed to reduce the influence of radiopharmaceutical accumulation outside of the 
thyroid. However, a certain proportion of blood and tissue accumulation above and 
below the thyroid will contribute to the assessment. An assessment of extra thyroidal 
uptake may be made by undertaking a background measurement on the leg, taken 
as an approximation to the neck. Subsequent measurements can be background 
corrected based on this value. 
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6.5.6 Interfering food/medications 
 
Both the BNMS and SNM guidelines outline the issues surrounding excessive 
dietary intake of iodine prior to the assessment. This is negated by patient 
counselling prior to the assessments. 
 
6.5.7 Contamination of the neck phantom 
 
Radioactive contamination of the neck phantom will result in a falsely high count rate 
when measured. Any increase in phantom count rate when compared to the patient 
will result in a lower assessment of the thyroid uptake. Radioactive contamination of 
the neck phantom may be identified as an unusually high count rate compared to 
that expected. Radioactive contamination monitoring of the phantom using a suitable 
radiation monitor would be able to distinguish between an issue with the ambient 
background or if indeed the phantom has become contamination. If the latter is true, 
the phantom would not be suitable for thyroid uptake assessments until fully 
decontaminated (either via decontamination techniques or allowing for sufficient 
natural radioactive decay). 
 
6.5.8 Recent administration of other radionuclides 
 
Any other recent administrations of radiopharmaceuticals to the patient may produce 
erroneous results. The effective half-life of the competing radiopharmaceutical needs 
to be borne in mind when considering the appropriateness of a thyroid uptake 
assessment following other administrations. 
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6.6 Monte Carlo modelling of a thyroid uptake counter 
 
Monte Carlo techniques have been previously used to model a thyroid uptake 
counter. Scarboro et al. (2009) detailed the MCNP modelling of a Captus 3000 
thyroid uptake counter and the associated validation measurements for a number of 
radionuclides. The potential application suggested by the authors was to use the 
thyroid uptake monitor as a screening and internal dosimetry tool in the event of a 
radiological incident. 
 
Monte Carlo techniques have also been used to address some of the uncertainties 
identified in the previous sections. Kramer and Crowley (2000) undertook MCNP 
simulations of various thyroid sizes and shapes for 125I and 131I and found 
uncertainties in the thyroid uptake measurement to be dependant on detector size, 
neck to detector position and the radioiodine used. In a seperate paper, Kramer et al. 
(1997) investigated the optimisation of the thyroid uptake counter for 125I and 131I 
measurements. Using the EGS4 Monte Carlo code, Ulanovsky et al. (1997) 
modelled a thyroid uptake counter and simulated 131I variations in thyroid detector 
distance and angular shift. Uncertainties in the range of -32% to +17% were 
observed. In a separate paper, Monte Carlo simulations (written in Pascal) were 
undertaken for a 3" × 3" thyroid uptake detector and a thyroid and neck model 
(Venturini, 2003). A combined uncertainty of up to 18% was found for the photopeak 
efficiency when modelling a 12 year old thyroid (taken as the limit for the adult 
thyroid) and a 20 year old thyroid. Bento et al. (2012) described the PENELOPE 
modelling of a 2" × 2" NaI ORTEC detector. Uncertainty in thyroid monitoring arising 
from varying neck to detector distance was found to be 12-38%.  
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6.7 Aims of the study 
 
The current published literature has identified some of the issues with accurate 
assessment of radioiodine thyroid uptake. Variations in collimator to neck distance, 
lateral displacement of the detector and thyroid depth have been acknowledged as 
factors in limiting the reliability of the thyroid uptake assessment accuracy. Some 
authors have suggested possible correction strategies for the uptake measurement, 
for example using the ratio of different parts of the acquired gamma spectrum to 
determine correction factors (Martin and Rollo, 1977) (Ośko et al., 2007) (Shapiro et 
al., 2014). However, this previous work has predominantly been undertaken 
experimentally, with the inherent limitations implied by this approach. 
 
The purpose of the following investigations is to use Monte Carlo simulations to 
determine the degree of uncertainty for the particular thyroid uptake counter used 
within the Medical Physics Department of the University Hospital of Wales. Also, for 
the particular case of thyroid depth, produce a depth based thyroid correction 
strategy for 123I thyroid uptake assessments that can reasonably be adopted into 
routine clinical practice  
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CHAPTER 7: MONTE CARLO THYROID UPTAKE COUNTER 
MODEL AND VALIDATION 
 
7.1 Introduction 
 
The core components of a thyroid uptake counter include a collimator, a scintillation 
crystal, a PMT, amplifier electronic circuitry and pulse height determination 
electronics. The main difference between a thyroid uptake counter and a gamma 
camera is that the gamma camera will usually consist of 60 or more PMTs and the 
signal processing electronics are designed to produce an image of the 
radiopharmaceutical distribution. A thyroid uptake counter usually employs a single 
PMT for non-imaging applications. 
 
In this chapter an overview of radiation detection using scintillators is presented 
along with a description of the thyroid uptake counter subject to the Monte Carlo 
simulations. The Monte Carlo model is detailed and validation is documented against 
practical measurements to determine the model‟s suitability for further investigation. 
 
7.2 Radiation detection using scintillation detectors 
 
The principle of radiation detection using a scintillation detector relies on the 
interaction of gamma and x radiation within the scintillation crystal. Scintillation 
crystals are generally hygroscopic and hence require the crystal and PMT to be 
sealed in an outer assembly to prevent any moisture ingress (Prekeges, 2011). The 
most commonly utilised scintillator crystal in nuclear medicine is NaI(Tl). At nuclear 
medicine diagnostic photon energy ranges, the predominant interaction between the 
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incident photon and NaI(Tl) is the photoelectric effect. Above these energies, 
Compton scattering predominates and the detection efficiency of NaI(Tl) begins to 
fall (Cherry et al., 2003). Incident photon energies greater than 1.02 MeV are 
required for pair production interactions, which falls outside the typical diagnostic 
nuclear medicine energy range. 
 
These interactions will cause excitation of the electrons in the crystal and a 
subsequent release of optical photons when the electrons fall back to their lower 
energy levels, via a colour centre. The amount of light produced is proportional to the 
incident radiation and therefore energy discrimination is possible.  
 
The NaI(Tl) crystal is coupled to a PMT which is designed to detect the light emitted 
as a result of radiation interactions within the crystal. Light from the crystal hits the 
photocathode and this results in the emission of photoelectrons via the photoelectric 
effect. These electrons are accelerated to a nearby dynode, which is held at a 
positive potential with respect to the photocathode. When the electrons strike the 
dynode at speed this causes the emission of more electrons. This continues for 
several dynodes until the final dynode in the chain (anode) where the current 
produced by the electrons passes out of the PMT. Typical electron gain factors for a 
PMT with nine to twelve dynodes would be of the order of one million (Prekeges, 
2011). The voltage pulse is further subjected to electronic amplification and pulse 
shaping within the assembly electronics to produce a voltage pulse that is suitable 
for pulse height analysis. 
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In theory, a radioactive source that emits single energy photons should produce a 
single value of voltage pulse when detected by a scintillation detector. However, a 
spread of values will be observed because of the variations in the processes of 
photon conversion to an electrical pulse. These include inefficient conversion of the 
incident photon energy into light photons in the crystal, fluctuations in the high 
voltage applied to the PMT and electrical noise in the system electronics. When the 
distribution of pulse height values is plotted it will take the form of a Gaussian curve 
(Prekeges, 2011). 
 
It is often beneficial to the operator to selectively count the radiation arising from a 
particular part of the displayed spectrum. This may be due to the fact that there are 
two or more radionuclides in a given sample or to count over the photopeak of the 
radionuclide to selectively remove Compton scatter regions (the Compton band is a 
separate feature of the spectrum due to the escape of the scattered photon and 
hence partial energy deposition). A voltage window can be selected to count only 
over a particular energy range of interest in the spectrum. This can be achieved 
because the electrical signal produced by the detector is proportional to the incident 
photon energy. The size of the detected signal is represented as a voltage level and 
a window can be placed around the central photopeak energy. Providing that the 
detector is calibrated against at least two known gamma energy sources it can also 
be used to measure photopeak energies. 
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7.3 Canberra detector system 
 
The thyroid uptake detector system used for the investigations is the 802-2×2 
detector manufactured by Canberra (Canberra, 2009). The detector system broadly 
consists of a scintillation crystal, a PMT, an internal magnetic light shield and a 14-
pin connector. The 14-pin connector is connected to a pre-amplifier and is also 
supplied from an external high voltage power supply. The whole assembly is 
encased within aluminium housing. The scintillation detector is a hermetically sealed 
assembly which includes a 51 × 51 mm NaI(Tl) crystal. The detector is housed within 
a lead outer shield which also incorporates a removable diverging lead collimator (1 
cm thick at the entrance). The inner diameter at the entrance of the collimator is 9 
cm with an inner diameter of 5.3 cm to the face of the detector. The dimensions of 
the collimator are consistent with the IAEA recommendations for the calibration and 
standardisation of thyroid uptake measurements (IAEA, 1962). The shielded detector 
is attached to a Panax stand that allows manoeuvrability of the detector unit (Figure 
7.1). 
 
 
Figure 7.1: Picture of the Canberra detector system and Panax stand 
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7.3.1 Multichannel analyser 
 
The high voltage to the PMT is supplied by a Canberra ASA-100 MCA module 
(Canberra, 2001). The MCA has 1024 channels to allow for energy discrimination. 
The high voltage, coarse gain and fine gain are set to determine the energy range 
and location of radionuclide peaks within the acquired spectra. The MCA is 
controlled using GENIE™ 2000 Gamma Acquisition and Analysis Version 3.1 
software (Canberra, 2006). The MCA can be operated in time mode, where data is 
acquired for a pre-set time, or count mode, where data is acquired until a single 
channel or group of channels registers a pre-set number of counts.  
 
7.3.2 Optimisation of acquisition parameters 
 
Before using the Canberra system to acquire data, a process of optimisation is 
required to ensure that the system is correctly calibrated and set up prior to use. For 
123I, the upper and lower discriminator levels were set to 1.5% and 100% 
respectively. As the investigations include the analysis of the spectral x-ray 
emissions of 123I, raising the lower discriminator level above 1.5% was not desirable. 
For routine clinical applications, it is customary to set the variables that affect the 
system gain, such as the applied PMT voltage and electronic amplification, to ensure 
that the principal gamma peak is in the middle of the spectral display. Replicating the 
clinical application is desirable in these investigations to determine some of the 
inherent sources of uncertainty in the uptake assessment. A summary of the 
parameters employed for the MCA can be seen in Table 7.1. 
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GENIE™ 2000 
Menu Option 
Parameter Setting 
ADC 
Lower level discriminator 1.5% 
Upper level discriminator 100.0% 
Channels Channels 1024 
Amp 
Coarse gain 256× 
Fine gain 1.51× 
Input mode Amplifier 
HVPS HV on 900V 
Table 7.1: GENIE™ 2000 MCA parameters 
 
7.3.3 GENIE™ 2000 software analysis tools 
 
The GENIE™ 2000 software (Version 3.1) allows for ROIs to be selected on the 
displayed spectrum. For thyroid uptake assessments, a consistent selection of ROIs 
is required for the comparison of a spectrum from the patient to that of a radioactive 
standard. The GENIE software will allow auto-selection of ROIs based on Gaussian 
modelling of the gamma peaks. However, this has the potential to cause variable 
ROI selection depending on the shape of the gamma peak. Therefore for thyroid 
uptake counting, the ROI is predetermined with the same defined start and end 
points for both patient and phantom measurements. 
 
An example of a screen capture of the GENIE™ 2000 user interface can be seen in 
Figure 7.2.  
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Figure 7.2: GENIE™ 2000 user interface showing a 123I spectra 
 
7.4 Energy Calibration 
 
Energy discrimination is an inherent property of a scintillation detector system and is 
influenced by the high voltage, electronic gain and also the energy resolution of the 
system. An energy calibration must be undertaken to relate the energy of the 
photons detected by the system to a particular channel number. When un-calibrated, 
the x-axis of the spectrum displays channel numbers between 1 and 1024. As a 
minimum, at least two distinct incident gamma energies must be used to produce a 
calibration. However, it is preferable to use more than two energies to improve the 
accuracy of the calibration. The calibration order of fit can also be varied up to a 
maximum of a third order fit, dependant on the number of distinct calibration points 
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used. The GENIE™ 2000 software platform allows for a number of calibrations to be 
undertaken that can be saved as separate calibration files to be recalled at a later 
date. To ensure good concordance with the Monte Carlo simulation, it is therefore 
important that the calibration is accurate in this range. 
 
7.4.1 Calibration of the Canberra system 
 
The choice of radionuclides to use for calibration will depend on local availability and 
the intended use of the system. Generally, sealed radioactive sources are preferred 
to reduce any possible radioactive contamination. Radionuclides with longer half-
lives are usually sealed to ensure they have a longer working use. For thyroid uptake 
assessments using 123I, a calibration range of 0 - 320 keV would place the main 
gamma emission in the centre of the spectral display. 
 
The radionuclides used for energy calibration were: 241Am, 99mTc, 57Co, and 123I. 
241Am and 57Co were sealed sources with activities in the kBq range. 99mTc and 123I 
were unsealed and underwent a dilution process to reduce the activities to several 
kBq. The unsealed sources were secured in a plastic aliquot bottle. The principal 
emissions of each of these radionuclides have been documented previously in Table 
4.7. These radionuclides are chosen specifically to span both the characteristic x-ray 
and the principal gamma emission. Initially, 241Am and 57Co were placed on the 
surface of the detector and an acquisition was undertaken for 30 minutes. A further 
two independent acquisitions were acquired using 57Co and 123I. Similar to the 
activity linearity issues that may be experienced with a radionuclide calibrator, 
scintillation detectors may suffer from dead time losses at high incident photon rates. 
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The Canberra detector does apply a counting time correction for dead time losses. 
However, the reported dead time was constrained to less than 5% in all calibration 
acquisitions. 
 
A total of four calibrations were undertaken and as summarised in Table 7.2. The 
calibration equations for each of the four calibrations are shown in Table 7.3. 
 
Radionuclide 
3 Source, 
1st Order 
3 Source, 
2nd Order 
4 Source, 
1st Order 
4 Source, 
2nd Order 
241Am     
57Co     
99mTc     
123I     
Table 7.2: Combination of radioactive sources used for each of the four calibrations 
 
Calibration Calibration Equation 
3 Source, 1st Order Energy = -7.55 + (0.4163×ChNumber) 
3 Source 2nd Order Energy = 4.364 + (0.3077×ChNumber) +(0.0002169×ChNumber
2
) 
4 Source 1st Order Energy = -8.791 + (0.4232×ChNumber) 
4 Source 2nd Order Energy = 0.2049 + (0.346×ChNumber) + (0.0001392×ChNumber
2
) 
Table 7.3: Calibration best fit equations for each of the four calibrations 
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7.4.2 Calibrated 123I spectra 
 
Once the energy calibration has been undertaken and the calibration files generated, 
they can be recalled and applied to subsequent spectral acquisitions. 
 
Figure 7.3 shows the 123I spectrum used in the calibration with each of the different 
calibrations applied. The energy of the channel number corresponding to the peak x-
ray and gamma positions are shown in Table 7.4 for each calibration. 
 
 
Figure 7.3: Graphical representation of the acquired 123I spectra with the application 
of four different calibrations 
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Calibration 
X-ray Peak 
keV 
Gamma peak 
keV 
3 Source, 1st Order 24.1 156.5 
3 Source 2nd Order 29.0 159.7 
4 Source 1st Order 23.4 158.4 
4 Source 2nd Order 27.3 158.1 
Table 7.4: X-ray and gamma peak energy for each calibration 
 
7.4.3 Calibrated 123I spectra discussion 
 
Figure 7.3 demonstrates that there are differences in the positions of the x-ray and 
the gamma peaks when applying each of the calibrations to a acquired spectra. 
NaI(Tl) crystals demonstrate a non-linear energy response which is reflected in the 
observed spectra. The expectation is that the higher order calibrations will more 
accurately correlate to the Monte Carlo simulations because of the non-linear energy 
resolution of the crystal. This is indeed shown in Table 7.4. The average emission 
weighted energy of the x-rays is 28.1 keV and the principal gamma emission is 159 
keV. The two second order calibrations appear to best match both the x-ray and 
gamma emissions of 123I.  
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7.5 Energy Resolution 
 
One of the main characteristics of the detector which is evident from Figure 7.3 is the 
broadening of the spectra peaks, commonly expressed as the energy resolution. An 
element of broadening would be expected for the x-ray peak due to the number of 
discrete emissions over a small energy range. However, the gamma peak is also 
broadened and the reasons for such broadening are discussed in section 7.2.  
 
The energy resolution of the Canberra detector is an important parameter to 
characterise for subsequent Monte Carlo simulations. The energy resolution is 
typically expressed as: 
 
EnergyPhotopeak
FWHM
ResolutionEnergy  .....Equation 7.1 
 
Where the FHWM is the full width of the photopeak in keV at half the peak maximum 
count. The energy resolution is also commonly expressed as a percentage and is 
non-linear, typically decreasing at higher incident photon energies. 
 
For the x-ray and gamma peaks in the 123I spectrum, the FHWM can be calculated 
by fitting a Gaussian curve to the peak. The Gaussian curve distribution takes the 
form of: 
2
2
2σ
μ)(x
e
2πσ
1
G(x)



...Equation 7.2
 
 
Where σ is the standard deviation and µ is the mean value. 
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G(x) is a maximum when x = µ: 
 
2πσ
1
μG  ..Equation 7.3 
Let half maximum  x = xH: 
  2
2μ)H(X
2σe
2πσ
1
2π2σ
1
2
μG


...Equation 7.4
 
 
2
2
H
2σ
μ)(X
e
2
1



...Equation 7.5 
 
 
2
2
H
e
2σ
μ)(x
2ln


...Equation 7.6
 
 
 2ln2σμX e
2
H  ...Equation 7.7 
 
μ(2)2lnσX eH  ...Equation 7.8 
Therefore 
(2)2ln2σ(2)ln2σ2FHWHM ee
2  ...Equation 7.9 
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7.5.1 Assessment of Canberra energy resolution 
 
To fully characterise the energy resolution of the Canberra system, spectral 
acquisitions of 123I, 57Co and 99mTc were undertaken. Each radionuclide spectrum 
was acquired with the source placed on the detector surface until at least 10,000 
counts were acquired within the peak [10,000 counts yield an approximate 1% 
counting uncertainty within the peak].  
 
The spectra were exported from the GENIE™ 2000 software and imported into 
Excel™ (Microsoft corp) for analysis. The solver function within Excel™ was utilised 
to fit a Gaussian curve to the peaks and calculate the standard deviation. Equations 
7.9 and 7.1 were used to calculate the FWHM and energy resolution.  
 
The FWHM and energy resolution results for each of the calibrations are shown in 
Table 7.5. 
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Radionuclide 
FWHM 
(keV) 
Energy resolution 
(%) 
Three source 1st order   
123I X-ray 6.93 24.69 
57Co 13.86 11.36 
99mTc 14.81 10.58 
123I 16.43 10.34 
Three source 2nd order   
123I X-ray 5.73 20.41 
57Co 15.15 12.42 
99mTc 16.38 11.70 
123I 18.50 11.64 
Four source 1st order   
123I X-ray 7.14 25.47 
57Co 14.53 11.91 
99mTc 15.30 10.71 
123I 16.26 10.23 
Four source 2nd order   
123I X-ray 6.19 22.04 
57Co 14.81 12.14 
99mTc 15.69 11.21 
123I 17.73 11.15 
Table 7.5: FWHM values and energy resolutions for each radionuclide 
 
The variation of percentage energy resolution with energy for each of the calibrations 
is shown in Figure 7.4. A polynomial quadratic equation has been fitted in Excel™ to 
each of the curves. 
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Figure 7.4: Energy resolution values as a function of emitted energy for each 
calibration 
 
7.6 Monte Carlo model of the Canberra detector 
 
Other authors (Dewji, 2009) (Davies, 2012) have produced MCNP models of the 
Canberra detector used in the following investigations. However, the MCNP model 
used for the simulations was produced, validated and investigated independently of 
previous work (unless otherwise stated). The dimensions and composition of the 
detector were obtained from published technical data (Canberra, 2011) and where 
such information was not available, direct measurements and/or estimations of the 
detector system were undertaken.  
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7.6.1 Geometrical structure of the Canberra detector 
 
Similar to the modelling of the Fidelis calibrator in Chapter 4, the Canberra detector 
can be modelled as a series of cylindrical surfaces within the MCNP5 code. The 
NaI(Tl) crystal is 51 × 51 mm and is surrounded by a 1.6 mm thick aluminium oxide 
reflector. Behind the crystal is the PMT. All of the components are encased in 
aluminium and contained within a lead shield. The specifications of the collimator are 
detailed in chapter 7.2.   
 
7.6.2 Material composition of the Canberra detector 
 
The specifications of the materials can be found in Table 7.6. The PMT is modelled 
as a vacuum. Material compositions are given as a percentage by weight. 
 
 Crystal Reflector Casing Lead casing PMT 
Materials 
(% Split) 
15% Sodium 
85% Iodine 
47% Oxygen 
53% Aluminium 
100% 
Aluminium 
100% Lead Vacuum 
Density 
(g cm-3) 
3.67 0.55
a
 2.7 11.35 - 
Table 7.6 material composition of the Canberra detector 
a density for the reflector taken from Dewji (2009). 
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7.6.3 Input file 
 
The cell and surface cards for the Canberra detector model are shown below. A new 
macro body is introduced into the model, namely a Truncated Right-angle Cone and 
is described as: 
 
TRC vx vy vz hx hy hz Rbase Rtop 
 
where Rbase is the radius of the base and Rtop is the radius of the top of the cone. The 
other surface macro bodies are as previously described.  
 
 
 
A cross-sectional visualisation of the Canberra detector is shown in Figure 7.5. 
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Figure 7.5: Cross-sectional visualisation of the Canberra detector 
 
Figure 7.6 shows a 3D visualisation of the NaI(Tl) crystal and PMT with the 
aluminium case. Here the white tube is representative of the PMT and the blue 
region for the crystal. 
 
 
Figure 7.6: Canberra detector in the aluminium casing 
 
Page | 136 
 
Figure 7.7 shows the location of the collimator with respect to the detector. The base 
of the collimator sits 2 cm in front of the surface of the detector. An aerial view of the 
collimator towards the detector shows the convergent nature of the collimator (Figure 
7.8). 
 
 
Figure 7.7: Canberra detector in the casing along with the collimator 
 
 
Figure 7.8: Aerial view of the collimator looking towards the detector. This shows the 
converging nature of the collimator from entrance to crystal face 
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Figure 7.9 shows the encapsulation of the detector in the lead casing against the 
collimator. 
 
 
Figure 7.9: Encapsulation of the detector in the lead shield along with the connection 
with the collimator 
 
7.6.4 Gaussian energy broadening 
  
As previously described, in an imperfect detector there will be broadening of the 
spectral peaks. Previous work was undertaken in section 7.5 to characterise the 
relationship between the FWHM and the energy of the incident photons. For 
accurate Monte Carlo modelling, the relationship between the FWHM and incident 
energy must be incorporated into the model. 
 
Page | 138 
 
The Gaussian energy broadening function is described in the MCNP5 manual (X-5 
Monte Carlo Team, 2003). The tallied energy is broadened by sampling from the 
Gaussian: 
𝑓 𝐸 = 𝐶𝑒 −  
𝐸−𝐸0
𝐴
 
2
...Equation 7.10 
 
where E is the broadened energy, E0 is the un-broadened energy of the tally, Ce is a 
normalisation constant and A is the Gaussian width. 
 
The Gaussian width is related to the full width half maximum (FWHM) by: 
 
𝐴 =
𝐹𝐻𝑊𝑀
2 ln⁡(2)
 ... Equation 7.11 
 
The FWHM is specified by the user by providing the constants a, b and c to fit the 
following relationship: 
 
𝐹𝐻𝑊𝑀 = 𝑎 + 𝑏 𝐸 + 𝑐𝐸2...Equation 7.12 
 
The estimation of the constants was undertaken on the 123I, 57Co and 99mTc spectral 
acquisitions described in section 7.5.1. An initial estimation for each constant was 
made to match as closely as possible the calculated FWHM from Equation 7.9 to 
that specified in Table 7.5. The square of the difference between the measured 
FWHM and that calculated from Equation 7.9 was also calculated. The solver 
function in Excel™ was used to minimise the square of the differences through an 
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iterative process of adjusting values of the constants. This continued until the change 
in the values was negligible.  
 
The constants calculated for each of the calibrations are shown in Table 7.7. A 
graphical representation of the Gaussian fits is shown in Figure 7.10.  
 
 
 
a b c 
3 Source, 1st Order 0.00091 0.03543 0.93948 
3 Source 2nd Order -0.00082 0.03693 4.27358 
4 Source 1st Order 0.00109 0.03568 0.93946 
4 Source 2nd Order -0.00116 0.04325 0.94004 
Table 7.7: Monte Carlo Gaussian energy broadening coefficients 
 
Figure 7.10: Calculated Gaussian energy broadening response for each of the 
calibrations 
Page | 140 
 
7.6.5 Tally card 
 
The tally card used in the simulations is different to that previously used for the 
Fidelis calibrator simulations. 
 
 
 
F8 is the pulse height tally specification in MCNP5 and details the normalised 
number of particles within a particular energy bin per starting particle. As previously 
described, the tally can be modified by a Gaussian energy broadening function, with 
the coefficients entered on the next line. In this case, the coefficients corresponding 
to the three source second order calibration were entered. The next line details the 
energy binning for the tally to apply. All 1024 energy channels are specified unless 
the calibration has resulted in negative energies. In this case only the positive energy 
bins are stated. 
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7.7  Monte Carlo model validation 
 
A number of investigations were carried out to validate the Monte Carlo model 
against physical measurements undertaken on the Canberra system. The first 
assessment undertaken was to determine the most appropriate energy calibration to 
continue with further investigations.  
 
7.7.1 Monte Carlo calibration modelling 
 
The effect of different calibrations on the apparent central energies of the spectral 
peaks has been previously documented. The most appropriate energy calibration 
must be selected for the Monte Carlo simulations to give the best concordance 
between the Canberra detector and the model. 
 
To determine the most appropriate calibration, an aliquot of 123I was placed on the 
surface of the Canberra detector. The aliquot was placed directly on the surface of 
the detector to minimise scatter within the displayed spectrum. A spectrum of the 123I 
aliquot was acquired until 10,000 counts had been tallied in a single channel.   
 
To remove any uncertainties about source material composition in the Monte Carlo 
model, initial simulations were undertaken using a radionuclide solution without a 
container. The aliquot was therefore water based and suspended 0.1 mm above the 
surface of the detector. 
 
A cross-section of the Monte Carlo model can be seen in Figure 7.11. 
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Figure 7.11: Water aliquot of 123I suspended 0.1 mm from the front surface of the 
detector 
 
A total of 1×108 123I histories were simulated. A high number of particles were 
simulated in this instance to improve the statistical significance of each energy tally 
bin (considering there are 1024 independent channels). 
 
Figure 7.12 shows the Vised visualisation of 10000 particles simulated from the 
radionuclide solution and the collision points. 
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Figure 7.12: Vised visualisation of the collision points for 10000 particles simulated 
 
The spectral display of the Monte Carlo simulations for each calibration as compared 
to the real 123I acquisitions can be seen in Figures 7.13 - 7.16. Each spectrum has 
been normalised to the maximum value (counts or pulses) which in this instance 
occurs within the x-ray peak. 
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Figure 7.13: Three source first order comparison of the Monte Carlo and Canberra 
spectra 
 
Figure 7.14: Three source second order comparison of the Monte Carlo and 
Canberra spectra 
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Figure 7.15: Four source first order comparison of the Monte Carlo and Canberra 
spectra 
 
Figure 7.16: Four source second order comparison of the Monte Carlo and Canberra 
spectra 
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7.7.2 Discussion 
 
Each of the four simulated curves shows similar spectral characteristics to the 
Canberra system. Both the x-ray and principal gamma peaks are identifiable on the 
Monte Carlo simulations. In each case, the degree of modelled spectral broadening 
appears to be in keeping with the physical system characteristics.  
 
A peak at 75 keV is also apparent in the Monte Carlo and Canberra spectra. This is 
due to K-alpha (L-shell transition) emissions from lead. A single peak is noted which 
is the combination of 72 keV and 75 keV emissions. 
   
Each of the Canberra spectra are also characterised by a peak at approximately 185 
keV, which is not replicated on the Monte Carlo modelled spectra. This peak is likely 
due to the summation of the 159 keV gamma peak and the average x-ray emissions. 
Emissions from the 123I source have resulted in both a characteristic x-ray emission 
and the principal gamma emission being detected by the Canberra system at the 
same time. This has therefore resulted in a count being registered for the combined 
energy of the characteristic x-ray and the principal gamma emission, at 
approximately 185 keV. As the Monte Carlo code simulates particle histories 
sequentially, this summation peak will not be observed in the modelled spectra. 
 
It is obvious from the two first order calibrations that there is a discrepancy with the 
peak location of the x-ray between the modelled and Canberra spectra. Visual 
inspection of each of the models implies that the four source 2nd order calibration 
curve and Gaussian energy broadening coefficients are the most appropriate in 
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terms of accurately representing the physical geometries. To confirm this, the square 
of the differences between the Monte Carlo model and the Canberra was calculated 
for two regions corresponding to channels 56 – 109 for the x-ray peak and channels 
353 – 448 for the principal gamma peak. The results are summarised in Table 7.8. 
 
Calibration 
X-ray peak 
(56 – 109 ch) 
Gamma Peak 
(353 – 448 ch) 
3 Source, 1st Order 7.10 0.71 
3 Source 2nd Order 2.05 0.16 
4 Source 1st Order 9.11 0.07 
4 Source 2nd Order 0.33 0.05 
Table 7.8: Sum squares of the difference between the x-ray and gamma peaks for 
the Monte Carlo models and Canberra system. The lower the value indicates the 
best concordance between the two spectra 
 
It can be seen from Table 7.8 that the four source 2nd order fit provides the closest 
resemblance to the physical detector for this particular geometry. The Gaussian 
energy broadening coefficients and calibration for the four source 2nd order fit was 
therefore used for the subsequent validation modelling.  
 
7.7.3 Thyroid neck phantom model 
 
The next simulation undertaken was to see if the model could accurately reproduce 
the physical system when a scattering medium is simulated.  
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The thyroid uptake neck phantom used for clinical patient measurements was used 
for this assessment. The neck phantom is 15 cm long and has a radius of 15.4 cm. 
The centre of the aliquot is at a depth of 2.25 cm in the neck phantom with 0.8 cm of 
phantom material directly above the aliquot. As per routine protocol, the phantom is 
placed at 10 cm from the front of the collimator. 
 
The exact material composition of the phantom was not known and therefore two 
simulations were undertaken, one with the phantom material consisting of PMMA 
and one with polyethylene. The density of PMMA was 1.19 g cm-3 and that of 0.96 
polyethylene was g cm-3. 
 
Figure 7.17 shows a picture of the phantom located below the collimator. 
 
 
Figure 7.17: Thyroid neck phantom located below the Canberra detector 
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Figure 7.18 shows a Vised visualisation of the cross-section Monte Carlo geometry. 
A 3D visualisation of the same geometry can be seen in Figure 7.19. 
 
 
Figure 7.18: Cross-sectional thyroid neck phantom located below the Canberra 
detector 
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Figure 7.19: 3D visualisation of the thyroid neck phantom located below the 
Canberra detector 
 
The comparison of the Monte Carlo spectrum and that of the Canberra system for 
the defined geometry can be seen in Figure 7.20. In this instance normalisation is 
made to the main gamma peak. 
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Figure 7.20: Comparison of Monte Carlo simulation and Canberra system for a 123I 
aliquot within the neck phantom 10cm from the front of the collimator 
 
7.7.4 Discussion 
 
There are a number of spectral differences that can be seen in Figure 7.20 when 
compared to Figure 7.16. Firstly, a higher degree of Compton scatter can be 
observed in the region between the two peaks. The relative difference between the 
height of the x-ray peak and the gamma peak is also more pronounced for the 
phantom measurements.  
 
Between the PMMA and polyethylene models, there are slight differences as would 
be expected from different material composition and density. The normalised peak 
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height of the PMMA model is slightly below that of the polyethylene, a reflection of 
the increased density of the composition modelled.  
 
There is a discrepancy for the Monte Carlo model x-ray energies reported. There is 
approximately a 1 keV difference between the peak Monte Carlo x-ray and the 
Canberra x-ray.  
 
The main difference between the Monte Carlo simulations and the Canberra system 
is the relative heights of the x-ray and main gamma peaks. In this case, the 
normalisation is done to the main gamma peak and therefore the discrepancy is 
seen at the x-ray peaks. The reverse would be true if the normalisation was 
undertaken to the x-ray peaks.  
 
The relative difference in height between the peaks is likely to be due to the 
composition of the materials used or the geometry considerations of the thyroid neck 
phantom. Such a discrepancy was not observed for the simulation of the 123I source 
near the detector surface. The relative counts (proportional to height) of the peaks is 
subject to the modelling in chapter 8 and therefore warrants further validation work to 
ensure a consistent response between the model and Canberra system.  
 
Validation was undertaken for three different situations involving a point source in air, 
a point source behind PMMA at the collimator surface and a source dispersed in 
water bottle. As in the previous work, all practical and simulated measurements were 
undertaken with 123I. The validation was undertaken in a similar fashion to that 
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described by Scarboro et al. (2009) where count ratios were calculated for the same 
energy regions in the MCNP5 modelled spectra. 
 
7.7.5 Point source in air 
 
The point source in air model is designed to assess the relative peaks of the 123I 
spectra without the uncertainty introduced by additional materials.  
 
The 123I radionuclide solution consisted of a syringe with an active cylindrical 
dimension of 0.3 cm length and 0.23 cm radius. Encapsulation of the source within 
the syringe was modelled.  
 
Practical measurements were undertaken with the point source centred in the view 
of the detector at a number of distances between 1 cm and 50 cm in air in front of 
the collimator.  
 
The geometries were replicated in MCNP5 and a total of 1×108 photons were 
simulated for each distance. 
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7.7.6 Point source in air results 
 
A comparison of the Monte Carlo modelled and physical spectra for the case of the 
point source 5 cm in front of the collimator is shown in Figure 7.21. 
 
Figure 7.21: Comparison of the Monte Carlo model to the Canberra 
 
Figure 7.21 shows a good concordance in both the energy and x-ray and gamma 
peak heights for the Monte Carlo and Canberra assessments. This is in keeping with 
the assessments undertaken with the 123I source on the surface of the detector and 
shows point sources outside of the collimator can be modelled faithfully. 
 
All of the spectral assessments to date have been normalised to either the x-ray or 
gamma peak. However, as the Monte Carlo model reports the number of pulses 
deposited in the energy bin per starting particle, these values can be converted to 
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counts with the appropriate multiplication of the activity of the source, the total 
acquisition time and the emissions per disintegration.  
 
Before undertaking each of the measurements, the activity of the 123I source was 
assayed in a Capintec-CRC15R calibrator using a copper filter with the previously 
derived copper filter factor of 54. For the case of the 123I point source in 5 cm air, the 
activity of the source at the start time was 2.98 MBq. The acquisition was undertaken 
for 50 seconds and the number of emissions per disintegration for 123I is 1.72.   
 
The application of these correction factors to the raw Monte Carlo tallies is shown in 
Figure 7.22. 
 
 
Figure 7.22: Comparison of the Monte Carlo model to the Canberra for total counts 
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Figure 7.22 shows a good concordance when the total number of counts is plotted 
for the Monte Carlo model and Canberra system. As the emission probability of 123I 
and the time of acquisition are well know, the main factor influencing the conversion 
to counts is the accurate activity determination of the source. Figure 7.22 therefore 
appears to validate the use of a copper filter with the appropriate calibration factor as 
an accurate tool for measuring 123I activity. 
 
To determine the relationship between the relative counts in the x-ray peak and the 
main gamma peak, for each acquisition, the ratio of the Monte Carlo normalised 
counts to the Canberra normalised counts was plotted at each distance for the x-ray 
and gamma peak. Normalised counts were used to negate the potential effects of 
dead time. Fixed ROIs for the entire normalised peaks were used (channels 48 – 
109 x-rays; 354 – 427 gamma). Table 7.9 shows the normalised ratios for the point 
source in air at each distance for the x-ray and gamma peaks. 
 
Distance 
(cm) 
X-ray peak ratio Gamma peak ratio 
1 0.915 0.994 
5 0.889 0.969 
10 0.877 0.955 
15 0.890 0.973 
20 0.904 0.983 
25 0.900 0.979 
30 0.902 0.988 
35 0.896 0.973 
40 0.901 0.992 
45 0.915 0.999 
50 0.903 0.991 
Mean 0.899 0.982 
3 × standard deviation 0.034 0.039 
Table 7.9: Ratio of the Monte Carlo and Canberra x-ray and gamma peak for various 
distances in air  
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Figures 7.23 and 7.24 show a graphical representation of the data presented in 
Table 7.9. Error bars indicate three standard deviations of the mean. 
 
Figure 7.23: Normalised count ratio for the x-ray peak 
 
Figure 7.24: Normalised count ratio for the gamma peak 
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7.7.7 123I source in a bottle 
 
A point source in air is useful to validate the model without any additional materials. 
However, it is not representative of the geometry of a thyroid. An assessment was 
therefore undertaken of an 123I solution dispersed in a plastic cylindrical bottle with a 
radius of 3.7 cm and a length of 11.5 cm (Astroplast Sterile Eyewash 500 ml). This 
geometry provides a scattering medium more akin to soft tissue. A similar 
assessment as previously described for the point source in air was undertaken with 
the water bottle moved from 5 cm to 50 cm from the front face of the detector. 
 
7.7.8 123I source in a bottle results 
 
Figure 7.25 shows the comparison between the spectrum for the Canberra and 
Monte Carlo simulation. 
 
 
Figure 7.25: Comparison of the Monte Carlo model to the Canberra 
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Again, we can see from Figure 7.25 that there is good agreement between the 
Monte Carlo model and the Canberra system. 
 
Table 7.10 shows the normalised ratios for the 123I solution at each distance for the 
x-ray and gamma peaks. 
 
Distance 
(cm) 
X-ray peak ratio Gamma peak ratio 
5 0.912 1.045 
10 0.884 0.999 
15 0.886 0.996 
20 0.897 1.001 
25 0.904 1.000 
30 0.880 0.989 
35 0.961 1.016 
40 0.917 1.019 
45 0.907 1.005 
50 0.892 1.000 
Mean 0.906 1.007 
3 × standard deviation 0.070 0.048 
Table 7.10: Ratio of the Monte Carlo and Canberra x-ray and gamma peak for 
various distances in air 
 
Figures 7.26 and 7.27 show a graphical representation of the data presented in 
Table 7.10. Error bars indicate three standard deviations of the mean. 
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Figure 7.26: Normalised count ratio for the gamma peak 
 
Figure 7.27: Normalised count ratio for the x-ray peak 
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7.7.9 Point source with PMMA 
 
Finally, to simulate the effect of depth, PMMA was placed on the surface of the 
collimator. Thicknesses of 1 cm to 8 cm were simulated with the point source behind 
the PMMA in the central field of the detector. The PMMA is useful as it simulates 
some scatter that will be encountered in the human measurements, but the added 
uncertainty is the material specification of the PMMA.  
 
7.7.10 Point Source with PMMA results 
 
Figure 7.28 shows the comparison between the spectra for the Canberra and Monte 
Carlo simulation for 4 cm thickness of PMMA in front of the collimator. 
 
 
Figure 7.28: Comparison of the Monte Carlo model to the Canberra 
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Table 7.11 shows the normalised ratios for the 123I point source with increasing 
thicknesses of PMMA. 
 
PMMA Thickness 
(cm) 
X-ray peak ratio Gamma peak ratio 
1 0.882 0.998 
2 0.867 0.972 
3 0.887 0.980 
4 0.912 0.993 
5 0.953 1.025 
6 0.965 1.021 
7 0.999 1.036 
8 0.973 0.999 
Mean 0.930 1.003 
3 × standard deviation 0.147 0.068 
Table 7.11: Ratio of the Monte Carlo and Canberra x-ray and gamma peak for 
increasing thicknesses of PMMA 
 
Figures 7.29 and 7.30 show a graphical representation of the data presented in 
Table 7.11. Error bars indicate three standard deviations of the mean. 
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Figure 7.29: Normalised count ratio for the gamma peak 
 
 
Figure 7.30: Normalised count ratio for the x-ray peak 
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7.7.11 Discussion of validation results 
 
The validation results indicate that the Monte Carlo model is an accurate 
representation for the Canberra detector for the measurement of 123I.  
 
Firstly, the results for the point source in air and the 123I source dispersed in the 
water bottle show consistent relationship when varying the source-detector distance. 
Unity is not achieved in terms of the ratios, and this is due to slight variations in 
compositions and geometries between the Monte Carlo model and the Canberra 
system. However, the ratio is effectively constant in both circumstances, which 
indicate good agreement between them. The significance of the slope for each case 
was tested and the P value was > 0.05 in all cases (implying no significant difference 
from zero). 
 
There is evidently more variation in the model with the varying thicknesses of PMMA. 
This variation is not reflected in the previous two circumstances and therefore it is 
likely to be an issue with the material composition. The fact that the x-ray ratio is 
affected more than the main gamma peak ratio gives more credence to this theory. 
However, it is noted that all measurements are within three standard deviations of 
the mean. Significance testing for the main gamma peak returned a P value > 0.05. 
However, a significant difference (P<0.05) was found for the x-ray ratios. 
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7.8 Summary 
 
In this chapter a Monte Carlo model of the Canberra thyroid uptake counter was 
produced and validated for a number of different circumstances. This has shown to 
produce acceptable agreement between what has been measured and what was 
simulated. 
 
The next stage of the investigations is to determine, using the Monte Carlo model, 
the degree of uncertainties for the Canberra thyroid uptake counter used within the 
Medical Physics Department of the University Hospital of Wales. Also, for the 
particular case of thyroid depth, determine a correction strategy for 123I thyroid 
uptake assessments that can reasonably be adopted into routine clinical practice. 
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CHAPTER 8: MONTE CARLO SIMULATION OF FACTORS 
INFLUENCING THE THYROID UPTAKE ASSESSMENT 
 
8.1 Introduction 
 
In the previous chapter a Monte Carlo model of the Canberra thyroid uptake counter 
was created and validation of the model was undertaken against the physical 
system. 
 
In this chapter, a model of the human thyroid gland is used to quantify some of the 
uncertainties identified in chapter 7. The three areas identified for assessment are: 
variations in neck to collimator distance, the effect of displacement of the detector 
and variations in neck tissue thickness. 
 
Finally, a correction strategy is devised for increasing thickness of tissues overlaying 
the thyroid. 
 
8.2 Modelling of a human thyroid 
 
The first stage of the investigations requires the Monte Carlo modelling of a human 
thyroid and neck anatomy. The anatomy and physiology of the thyroid gland was 
detailed in chapter 6. 
 
The main components of the thyroid to be modelled are the left and right thyroid 
lobes and the connecting isthmus tissue. The neck must also be modelled to allow 
for the physical attenuation (absorption and scattering) conditions to be replicated. 
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The neck also contains the trachea and windpipe. Other tissues within the neck are 
predominately soft tissues and are therefore collectively modelled as soft tissue 
within the neck. 
 
In the following simulations, no radioactivity is simulated emanating from outside of 
the thyroid. The influence of background radioactivity is therefore not considered. 
The major contribution to background radiation would be from tissues above and 
below the thyroid. Emissions emanating from tissues outside of the field of view 
would in most cases be attenuated by the lead collimator, unless scattered into the 
field of view. However, to permit realistic body geometry, a head, torso, arms and 
legs are also included in the model. 
 
8.2.1 Geometric structure 
 
The geometric structures of the simulated human are shown in Table 8.1 and are 
identical to the MCNP5 model produced by Davies (2012). Baseline data for the 
geometric structure of the head, lungs, trachea, thyroid and isthmus is based on data 
provided in ICRP Publication 23 (ICRP, 1975). Where such information is not 
available estimations were made. 
 
For simulation, the initial thickness of tissue overlying the thyroid is an important 
factor. ICRP (1975) gives the amount of overlying tissue in various age groups. The 
quoted values for a 15 year old female, 36 year old male and 38 year old female 
were 1 cm, 2 cm and 0.4 cm repesctively. Initially, simulations were conducted with a 
thyroid depth of 2 cm, in keeping with the baseline modeling data for reference man. 
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Body part Modelled geometry Dimensions 
Head Sphere Radius: 9.07 cm 
Thyroid Ellipsoid (two lobes) 
Length: 6.5 cm 
Width: 3 cm 
Depth: 1.75 cm 
Isthmus Cylinder 
Length: 2 cm 
Radius: 1 cm 
Trachea Cylinder 
Radius: 0.85 cm 
Length: 20 cm 
Thickness: 0.1 cm 
Air way Cylinder 
Radius: 0.75 cm 
Length: 20 cm 
Neck Cylinder 
Length: 12 cm 
Radius: 6 cm 
Torso Rectangle 
Length: 52.35 cm 
 Width: 30 cm 
Depth: 20 cm 
Arms Cylinder 
Length: 75 cm 
Radius: 3 cm 
Legs Cylinder 
Length: 90 cm 
Radius: 7 cm 
Lungs Rectangle 
Length: 28 cm 
Width 13/12 cm 
Depth 18 cm 
Table 8.1: Dimensions of the human model (adapted from ICRP (1975) for the head, 
lungs, trachea, thyroid and isthmus). 
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8.2.2 Material composition 
 
The material composition of each of the tissues in the model is shown in Table 8.2. 
The soft tissues are predominately water and so for ease of modelling, the majority 
of the tissues are regarded as water with a density of 1 g cm-3. For the thyroid gland, 
the quoted density is slightly greater at 1.051 g cm-3 (ICRP, 1975). 
 
Body part Composition 
Density 
(g cm-3) 
Head Water 1 
thyroid Water 1.051 
isthmus Water 1.051 
trachea Water 1 
Air way Air 0.0012 
Neck Water 1 
Torso Water 1 
lungs Air 0.0012 
Table 8.2: Material composition of the modelled reference man (density of the thyroid 
taken from ICRP (1975)) 
  
Page | 170 
 
8.2.3 Monte Carlo model 
 
The cell and surface cards for the Monte Carlo simulations are shown below. The 
thyroid counter model was transposed accordingly. 
 
 
 
A cross-sectional image of the Monte Carlo model through the neck along with a 
vised visualisation of the thyroid gland is shown in Figure 8.1. The thyroid depth of 2 
cm is taken from the midpoint of the thyroid lobes to the detector along the central 
axis. 
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Figure 8.1: Left: Cross-sectional visualisation of the human neck showing the two 
thyroid lobes, connecting isthmus tissues, trachea and wind pipe. Right: Vised 3D 
visualisation of the thyroid gland 
 
Figure 8.2 shows a cross-sectional visualisation of the detector and neck with the 
detector collimator entrance at 10 cm in front of the neck.  
 
Figure 8.3 shows a vised 3D visualisation of the detector centred at 10 cm from the 
top of the neck. The neck is not shown in the figure to allow for the thyroid gland 
location to be observed. 
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Figure 8.2: Cross-sectional visualisation of the human neck and detector. The 
entrance to the collimator is 10 cm above the surface of the neck 
 
 
Figure 8.3: Vised visualisation of the Canberra thyroid uptake counter centred over 
the thyroid at a collimator entrance to thyroid distance of 10 cm  
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8.2.4 Spectral display of 123I in the thyroid 
 
The initial modelled conditions previously described were used to obtain a spectrum 
of 123I emanating from the thyroid gland. The source definition for the Monte Carlo 
simulation is shown below. 
 
 
 
The source is defined as emanating from the thyroid tissues encompassing cell 
number 16.  A visual depiction of the starting source particle positions for 1000 
particles is shown in Figure 8.4. 
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Figure 8.4: Cross-sectional visualisation of the thyroid in the neck with the positions 
of 1000 starting particles. All the emissions are seen emanating from the thyroid 
tissues 
 
To create a spectrum of the 123I emissions from the thyroid, 3×107 particles were 
simulated. The normalised number of particles deposited in the simulated energy 
bins is plotted in Figure 8.5. 
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Figure 8.5: Normalised Monte Carlo simulation of 123I in the thyroid 
 
The spectrum clearly displays the x-ray and gamma peaks as previously seen during 
the validation work. A degree of noisiness of the data is also seen. This is a result of 
a reduction in the amount of particles being tallied in the crystal due to the distance 
of the thyroid uptake counter from the source and the scattering conditions. Such 
nosiness of the data is also evident in a clinical setting. 
 
8.2.5 Determination of x-ray and gamma peak windows 
 
The determination of the x-ray and gamma peak windows for comparative 
assessments was undertaken qualitatively based on the spectrum displayed in 
Figure 8.5. 
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The counting windows for subsequent assessments are shown in Table 8.3. 
 
Peak 
Energy Window 
(keV) 
X-ray 15.34 – 38.07 
Gamma 138.36 – 178.46 
Table 8.3: Energy window ranges 
 
For all the Monte Carlo assessments undertaken in 8.3 the relative error of the mean 
tally was below 0.05. 
 
8.3 Investigation of the effect of changing parameters associated with 
thyroid uptake measurement 
 
8.3.1 Vertical displacement of the detector 
 
The first simulations are concerned with varying the vertical position (x axis in the 
simulation) of the detector above the thyroid. In a clinical setting, a spacer may be 
employed to ensure a consistent approach to determining the vertical position of the 
collimator above the surface of the neck. However, as described in chapter 6, even a 
marginal change in distance, of the order of 1 cm, may produce a variation of up 6.6 
% in flux at the face of the detector. 
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To determine the relationship between vertical displacement and normalised counts, 
the collimator to neck distance was varied between 7 cm and 13 cm in increments of 
0.5 cm by moving the detector (this increases or decreases the distance travelled by 
radiation in air). Displacements outside of those stated are not deemed to be 
clinically likely.  
 
The results of varying the detector to thyroid distance can be seen in Table 8.4 and 
Figure 8.6. All results are normalised to 10 cm neck to collimator distance. 
 
Distance 
(cm) 
Normalised counts in x-
ray peak compared 
to 10 cm 
Normalised counts in 
gamma peak compared 
to 10 cm 
13 0.867 0.860 
12.5 0.880 0.878 
12 0.900 0.898 
11.5 0.923 0.922 
11 0.951 0.945 
10.5 0.974 0.971 
10 1.000 1.000 
9.5 1.025 1.031 
9 1.052 1.057 
8.5 1.087 1.088 
8 1.119 1.124 
7.5 1.150 1.153 
7 1.192 1.185 
Table 8.4: Normalised counts in the x-ray and gamma peaks 
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Figure 8.6: Variation in x-ray peak and gamma peaks counts with distance from the 
collimator to the neck 
 
8.3.2 Vertical displacement of the detector discussion 
 
As expected, the relationship between the normalised counts and the distance 
between the surface of the collimator and neck appears to be in keeping with the 
inverse square law. Based on the inverse square law, a change in vertical 
displacement between 32.89 cm and 33.89 cm from the surface of the neck to the 
detector surface would result in 5.8% variation in photon flux. The value measured 
was 5.5% based on the gamma peak measurements (corresponding to a 
displacement from 10 cm to 11 cm collimator to neck distance) but also accounts for 
a potential increase in scatter into each of the measurement windows. Even a 
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moderate change of 0.5 cm either side of 10 cm can produce an uncertainty of 3% in 
the number of photons deposited in the energy windows.  
 
8.3.3 Horizontal displacement of the detector 
 
A potential source of error which is more likely than vertical displacement error is the 
horizontal displacement of the detector. In this model, horizontal movements in the Z 
(medio-lateral) and Y (cranio-caudal) directions were modelled. Increments of 1 cm 
were made in the positive and negative directions to indicate misalignment of the 
detector. Figures 8.7 and 8.8 and shows a visualisation for misalignment of 5 cm in 
the Y and Z directions.  
 
 
Figure 8.7: Visualisation of the misalignment of the detector distally along the Y axis 
of the body 
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Figure 8.8: Visualisation of the misalignment of the detector laterally along the Z axis 
of the body 
 
The results are shown in Table 8.5 and Figures 8.9 and 8.10. 
 
Z 
Location 
Normalised 
counts in 
x-ray peak 
compared 
to Z0 
Normalised 
counts in 
gamma peak 
compared to 
Z0 
Y 
Location 
Normalised 
counts in x-ray 
peak compared 
to Y0 
Normalised 
counts in 
gamma peak 
compared to 
Y0 
Z5 0.636 0.662 Y5 0.727 0.766 
Z4 0.809 0.818 Y4 0.850 0.903 
Z3 0.929 0.948 Y3 0.935 0.985 
Z2 0.960 0.962 Y2 0.958 1.011 
Z1 0.987 0.983 Y1 0.970 1.004 
Z0 1.000 1.000 Y0 1.000 1.000 
Z-1 1.010 1.003 Y-1 1.008 0.991 
Z-2 1.000 0.984 Y-2 0.983 0.975 
Z-3 0.955 0.964 Y-3 0.947 0.965 
Z-4 0.859 0.823 Y-4 0.894 0.902 
Z-5 0.701 0.625 Y-5 0.757 0.767 
Table 8.5: Horizontal displacement ratios for the Z and Y directions 
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Figure 8.9: Variation of x-ray peak and gamma peaks counts with Z axis 
displacement 
 
Figure 8.10: Variation of x-ray peak and gamma peaks counts with Y axis 
displacement 
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8.3.4 Horizontal displacement of the detector discussion 
 
Figures 8.9 and 8.10 show the effect of detector displacement in the Z and Y axis 
directions. Considering the symmetrical nature of the geometries in the neck, it 
would be expected that a displacement in the Z direction would produce a 
symmetrical effect. In general, both the x-ray peak and the gamma peak variation 
are symmetrical. The negative Z direction tends to return higher values for both the 
x-ray and gamma peaks. This is likely to be due to slight geometrical uncertainties in 
either the MCNP5 input file or the reading of the file by the programme. A 3 cm 
deviation results in less than a 5.2% error in the uptake assessment, but rises 
sharply to 35% at 5 cm. 
 
A displacement in the positive Y direction is towards the head and the negative Y 
direction towards the feet. Considering the differences in potential scattering 
conditions in these directions, a completely symmetrical distribution is not likely to 
occur. The effect of movement towards the head seems to have a greater effect on 
the x-ray peak compared with movement towards the feet. Displacement up to 2 cm 
either side can be tolerated without significant effect on the gamma counts. A 4 cm 
displacement, however, could produce up to 10% error in the measured counts in 
the gamma peak.  
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Displacement of the neck in the medio-lateral (Z) direction appears to be the more 
critical than that in the cranio-caudal (Y) direction considering the potential 
consequences of misalignment. 
 
8.3.5 Thyroid depth in tissue 
 
The effect of thyroid depth is simulated by increasing the thickness of thyroid tissue 
between the thyroid and the collimator. This is achieved by increasing the radius of 
the neck. Because of the ellipsoidal shape of the thyroid gland, the distance from the 
thyroid to the edge of the neck varies depending on what point the measurement is 
undertaken. Therefore, the depth of the thyroid is taken as the midpoint depth of the 
thyroid lobes, which can be measured along the central axis to the detector. The 
reference thyroid depth is taken as 2 cm. Due to the cylindrical nature of the 
modelled neck, smaller depths were not possible with this configuration.  
 
Two simulations were modelled. In the first instance, the neck to detector distance 
was kept constant at 10 cm, as would be the case in clinical practice.  In the second 
instance, the detector remained at the same position with increasing thickness of 
tissue. 
 
The results are shown in Tables 8.6 and 8.7 and graphically displayed in Figures 
8.11 and 8.12. 
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Tissue thickness 
(cm) 
Normalised counts in x-
ray peak compared 
to 2 cm 
Normalised counts in 
gamma peak compared 
to 2 cm 
2 1.000 1.000 
2.5 0.845 0.919 
3 0.691 0.855 
3.5 0.581 0.800 
4 0.489 0.731 
4.5 0.408 0.686 
5 0.343 0.628 
5.5 0.295 0.581 
6 0.238 0.541 
Table 8.6: Increasing neck thickness: count ratios normalised to 2 cm depth (fixed 
collimator to neck distance of 10 cm) 
 
Tissue thickness 
(cm) 
Normalised counts in x-
ray peak compared 
to 2 cm 
Normalised counts in 
gamma peak compared 
to 2 cm 
2 1.000 1.000 
2.5 0.866 0.944 
3 0.728 0.903 
3.5 0.630 0.865 
4 0.536 0.814 
4.5 0.461 0.777 
5 0.392 0.727 
5.5 0.339 0.685 
6 0.283 0.656 
Table 8.7: Increasing neck thickness: count ratios normalised to 2 cm depth 
(collimator to neck distance not adjusted) 
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Figure 8.11: Variation in x-ray peak and gamma peaks with increasing depth of 
thyroid in tissue (fixed collimator to neck distance 10 cm) 
 
Figure 8.12: Variation in x-ray peak and gamma peaks with increasing depth of 
thyroid in tissue (collimator to neck distance not adjusted) 
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8.3.6 Thyroid depth in tissue discussion 
 
The relationship between normalised counts and thyroid depth appears to be 
exponential between 2 cm and 6 cm depth for the fixed collimator to neck distance 
and when the detector is not moved. 
 
For a fixed collimator to neck distance of 10 cm, a 1 cm increase in neck tissue 
thickness results in a 14% reduction in counts in the gamma peak. This increases to 
over 45% with a thyroid depth of 6 cm. With a fixed collimator to neck distance, there 
will also be an inverse square law component due to the increasing distance of the 
detector to the thyroid. When the collimator to neck distance is not adjusted, a 
reduced discrepancy of 10% is seen between 2 cm and 3 cm thyroid depth.  
 
8.3.7 X-ray to gamma peak ratio 
 
Table 8.8 shows the ratio of the x-ray and gamma peak counts with varying 
thickness of tissue when the collimator to neck distance is kept at 10 cm and when 
the collimator to neck distance is not adjusted. 
 
Figure 8.13 is a graphical representation of the data. The variation of this ratio with 
tissue depth when the detector to neck distance is not adjusted is very similar and 
not shown.  
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Fixed collimator to neck 
distance 10 cm 
Collimator to neck distance 
not adjusted 
Tissue 
thickness 
(cm) 
Ratio x-ray 
to gamma 
peak 
Normalised 
ratio x-ray to 
gamma peak 
to 2 cm 
Ratio x-ray 
to gamma 
peak 
Normalised 
ratio x-ray to 
gamma peak 
to 2 cm 
2 0.703 1.000 0.703 1.000 
2.5 0.646 0.920 0.644 0.917 
3 0.568 0.808 0.567 0.807 
3.5 0.510 0.726 0.512 0.728 
4 0.470 0.669 0.463 0.659 
4.5 0.418 0.595 0.416 0.593 
5 0.384 0.547 0.379 0.540 
5.5 0.356 0.507 0.348 0.495 
6 0.309 0.439 0.303 0.431 
Table 8.8: Ratio of the x-ray and gamma peak counts with varying thickness of tissue  
 
 
Figure 8.13: Ratio of the x-ray peak to the gamma peak (fixed collimator to neck 
distance 10 cm) 
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8.3.8 X-ray to gamma peak correction discussion 
 
Figure 8.13 shows a strong exponential correlation between the ratios of the counts 
measured in the x-ray peak to those in the gamma peak. In a clinical setting, it would 
be feasible to measure the counts within the x-ray peak to those in the gamma peak 
using the appropriate energy windows. The ratio of the counts in the x-ray and 
gamma peaks may then be cross referenced to Figure 8.13 to estimate the depth of 
the thyroid in the neck.  Once the depth of the thyroid is known, Figure 8.11 may 
then be used to determine the magnitude of the correction factor that needs to be 
applied to the gamma peak counts to correct for the error.   
 
8.4 Summary 
 
In this chapter the previously validated Canberra thyroid uptake counter Monte Carlo 
model was used to simulate a number of the recognised uncertainties in the thyroid 
uptake assessment. The vertical displacement of the collimator was shown to 
produce errors of up to 12% with a vertical displacement of 2 cm. The lateral 
movement of the detector in the medio-lateral and cranio-caudal directions was also 
found to be a source of error. Although less of a variation is seen over 2 cm in either 
direction compared to a vertical displacement, accurately centring the collimator over 
the thyroid gland is inherently more variable as the location of the thyroid in the neck 
is inferred. Therefore the more extreme misalignment situations may be encountered 
in clinical practice. 
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The variation in x-ray and gamma counts with increasing thyroid depth was also 
investigated. Again, the depth of the thyroid in the neck was shown to be a potential 
cause of error. A 2 cm increase in tissue thickness can result in a reduction of counts 
in the gamma peak approaching 27%.  
 
Finally, a correction strategy for the depth of the thyroid in the neck was presented. 
The ratio of the counts in the x-ray peak compared to the gamma peak can be used 
as the basis for correcting the depth of the thyroid tissue and therefore improve the 
accuracy of the thyroid uptake assessment.  
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CHAPTER 9: CONCLUSIONS AND FURTHER WORK 
 
9.1 Conclusions 
 
The use of MCNP5 Monte Carlo radiation transport simulation code has been shown 
to be suitable for modelling two common nuclear medicine pieces of equipment, 
namely a radionuclide calibrator and a thyroid uptake counter. 123I, with its low 
energy x-ray emissions, may have posed particular modelling issues for the MCNP5 
code since these emissions are near the low end of the specified validated energy (1 
keV). However, particularly when undertaking the thyroid uptake counter simulations, 
a high degree of concordance was seen between the physical and modelled spectra. 
Other validation work provided further reassurance that MCNP5 is a good tool for the 
medical physics simulations undertaken.  
 
This thesis covers two broad themes regarding issues surrounding 123I: its assay 
using a radionuclide calibrator and its use for the measurement of radioiodine uptake 
in the thyroid gland. 
 
Issues regarding 123I assay are well documented as described in section 3.6. 
However, the novel approach adopted in this thesis is the use of Monte Carlo 
techniques for the investigation of measurement uncertainties with the UK Fidelis 
secondary standard instrument.  It was shown that uncertainty in the region of 21% 
was expected when comparing 123I assay in syringe and in a vial. This value was 
somewhat lower than has been reported in the literature. Comparative simulations 
were also undertaken with the same chamber filled with argon. These confirmed the 
uncertainty, in the region of 60-80%, noted in the literature.  
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The observation of reduced uncertainty for 123I assay when using nitrogen as a 
chamber gas compared to argon, leads to the conclusion that nitrogen is preferable 
to argon if no correction strategies are employed. Even so, uncertainties in the 
region of 21% as found with the modelled syringe are still unacceptable, bearing in 
mind the principle of ALARP. Therefore, even for a nitrogen filled chamber, the 
application of suitable correction strategies is warranted. The particular correction 
strategy investigated in chapter 5 was the use of a copper filter.  For an nitrogen 
filled Fidelis chamber, a copper thickness of 0.3 mm would be sufficient to negate 
the influence of low energy x-rays on the ionisation current. Increasing the thickness 
of copper in this circumstance may not be desirable, as the Monte Carlo generated 
sensitivity curve for the nitrogen filled Fidelis chamber indicates reduced sensitivity 
when compared to argon. A 0.3 mm thick copper filter is therefore proposed for a 
nitrogen filled Fidelis chamber. 
 
As well as highlighting uncertainties in the assay of 123I, Monte Carlo modelling also 
had wider advantages by generating a sensitivity curve for the nitrogen-filled Fidelis 
chamber. Generating such a curve using experimental measurements with 
radionuclides can pose issues because of uncertain radionuclide emission data. 
There is certainly a role for modelling to negate such issues. The generation of new 
calibration factors (as described in chapter 5) can be undertaken by simulating the 
radionuclide and container combination, or by using the previously derived sensitivity 
curve. 
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The uncertainty associated with assaying 123I is of direct relevance to the thyroid 
uptake assessment with this radionuclide. Thyroid uptake assessment involves a 
comparative of the 123I activity in the thyroid gland to that of a radioactive standard 
embedded within suitable tissue equivalent material (neck phantom). Any difference 
in 123I measurement sensitivity between the receptacle used for the administration to 
the patient and that used in the thyroid phantom will inevitably result in an error in the 
uptake assessment.  
 
The second theme to the thesis was concerned with uncertainties associated with 
thyroid uptake assessment using the Canberra thyroid uptake counter. Variations in 
certain parameters and how they propagate to a clinical measurement have been 
documented in the literature previously. In this study, these issues were quantified 
for the particular case of a Canberra thyroid uptake counter. While the assessments 
undertaken looked at the effect of vertical and horizontal displacement of the thyroid 
uptake counter and thyroid depth with soft tissue as sources of error, other factors as 
outlined in chapter 6 will also contribute to the uncertainty in the uptake 
measurement.  
 
For the Canberra detector modelled, a 2 cm vertical displacement of the detector 
was shown to produce errors of up to 12%. The horizontal movement of the detector 
in the medio-lateral and cranio-caudal directions was also found to be a source of 
error, although to a lesser degree for a similar misalignment. The variation in gamma 
peak counts with increasing thyroid depth showed a 27% reduction in counts for an 
additional 2 cm of tissue anterior to the thyroid.  
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In terms of negating the uncertainties identified, two of the three sources of error can 
be reduced by careful operator preparation. Vertical errors are negated by using a 
spacer although horizontal displacement can be more difficult to correct while not 
knowing the exact location of the thyroid in the neck. Using a gamma camera can 
help reduce horizontal displacement errors either by using the camera itself for the 
uptake assessment or using it to aid localisation. However, the inherent poor 
sensitivity of a gamma camera compared to a thyroid uptake counter must be borne 
in mind. 
 
Finally, for the Canberra thyroid uptake counter a correction strategy for thyroid 
depth in tissue is proposed based on the differential counts in the x-ray and gamma 
peaks. This would be achieved by using a dual counting window over both the x-ray 
and gamma peaks for patient measurements. The relationship of the differential ratio 
fits an exponential curve to a high degree of correlation. The thyroid depth as 
estimated using Figure 8.13 can be applied to Figure 8.11 to correct for the depth of 
the thyroid. 
 
In chapter 1 the following hypothesis was proposed: 
 
“Monte Carlo techniques can be used to accurately simulate a radionuclide calibrator 
and thyroid uptake counter and quantify uncertainties with respect to 123I 
measurement” 
 
The work undertaken herein supports this hypothesis. 
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9.2 Further work 
 
Firstly, while useful work has been undertaken in modelling the Fidelis calibrator, 
there is scope for significant further work to explore different combinations of vials 
and syringes as containers of radioactivity. As previously stated, syringe factors do 
not currently feature in the NPL list of approved Fidelis calibration factors. Therefore, 
Monte Carlo simulations of a wide number of different syringes, validated against 
practical measurements, would be of benefit to Fidelis calibrator users. The Monte 
Carlo simulations undertaken in this thesis gave no consideration to a potential jig as 
a syringe holder for measurements in the Fidelis. A jig or set of jigs would need to be 
constructed for proper validation of the syringe factors for implementation into routine 
practice. 
 
In terms of a field radionuclide calibrator, a copper filter is routinely used to correct 
123I assays. Further modelling investigations could be undertaken regarding different 
filtering materials and the appropriate thickness of the materials to use. Monte Carlo 
modelling could also be used to investigate the effect of incorporating a suitable 
filtering material into the design of the calibrator. 
  
In terms of the thyroid uptake assessment, the depth of the thyroid is a significant 
source of error and suitable correction strategies are worth pursuing. While this 
thesis proposes a potential methodology based on Monte Carlo simulations, a 
significant amount of further work is required before incorporation into routine 
practice. The human model used for the investigations would require significant 
modification to fully replicate a human neck geometry and composition. Such data 
could be provided from ultrasound or CT scans and imported into MCNP5; this has 
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the potential to encompass the full range of anatomies seen in the human 
population. The effect of abnormal thyroid geometries on the differential x-ray and 
gamma peak ratios would also need careful consideration. 
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